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Sherri Y. Huang 
AP2IX-4, A CELL CYCLE REGULATED NUCLEAR FACTOR, MODULATES 
GENE EXPRESSION DURING BRADYZOITE DEVELOPMENT IN 
TOXOPLASMA GONDII 
 
Toxoplasma gondii is a ubiquitous, protozoan parasite contributing 
significantly to global human and animal health. In the host, this obligate 
intracellular parasite converts into a latent tissue cyst form known as the 
bradyzoite, which is impervious to the immune response. The tissue cysts 
facilitate wide-spread transmission through the food chain and give rise to 
chronic toxoplasmosis in immune compromised patients. In addition, they may 
reactivate into replicating tachyzoites which cause tissue damage and 
disseminated disease. Current available drugs do not appear to have appreciable 
activity against latent bradyzoites. Therefore, a better understanding of the 
molecular mechanisms that drive interconversion between tachyzoite and 
bradyzoite forms is required to manage transmission and pathogenesis of 
Toxoplasma.  
Conversion to the bradyzoite is accompanied by an altered transcriptome, 
but the molecular players directing this process are largely uncharacterized. 
Studies of stage-specific promoters revealed that conventional cis-acting 
mechanisms operate to regulate developmental gene expression during tissue 
cyst formation. The major class of transcription factor likely to work through these 
cis-regulatory elements appears to be related to the Apetala-2 (AP2) family in 
plants. The Toxoplasma genome contains nearly 70 proteins harboring at least 
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one predicted AP2 domain, but to date only three of these T. gondii AP2 proteins 
have been linked to bradyzoite development.   
We show that the putative T. gondii transcription factor, AP2IX-4, is 
localized to the parasite nucleus and exclusively expressed in tachyzoites and 
bradyzoites undergoing division. Knockout of AP2IX-4 had negligible effect on 
tachyzoite replication, but resulted in a reduced frequency of bradyzoite cysts in 
response to alkaline stress induction – a defect that is reversible by 
complementation. Microarray analyses revealed an enhanced activation of 
bradyzoite-associated genes in the AP2IX-4 knockout during alkaline conditions. 
In mice, the loss of AP2IX-4 resulted in a modest virulence defect and reduced 
brain cyst burden. Complementation of the AP2IX-4 knockout restored cyst 
counts to wild-type levels. These findings illustrate the complex role of AP2IX-4 in 
bradyzoite development and that certain transcriptional mechanisms responsible 
for tissue cyst development operate across parasite division.  
 
Gustavo Arrizabalaga, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
Toxoplasma gondii is a prevalent and versatile pathogen. This obligate 
intracellular parasite infects up to a third of the world population, and in certain 
countries, the seroprevalence reaches as high as 80% (1). The transmission of 
this parasite is multi-route, and patient populations that suffer the potentially fatal 
disease caused by this parasite include HIV/AIDS patients, patients receiving 
immunosuppressive therapies, organ transplant recipients, and developing 
fetuses (2).  
The role that bradyzoite tissue cysts play in the parasite’s success cannot 
be understated. T. gondii is able to infect virtually any warm-blooded animal, and 
the tissue cysts play an important role in transmission between intermediate 
hosts as they are prevalent and found in a wide range of animals (2). In its host, 
these tissue cysts are able to remain latent, but when a loss of immune response 
occurs, such as in immunocompromised patients, this parasite is able to 
reactivate, rupture tissues, and disseminate systemically where it causes further 
damage (2). There are no FDA-approved therapies that can eradicate the tissue 
cysts.  
Unfortunately, much of bradyzoite biology remains a mystery. At the basis 
of bradyzoite development is a cascade of gene expression changes; however, 
the key molecular players that direct this gene expression are unknown. The goal 
of this thesis is to characterize a putative transcription factor, AP2IX-4, whose 
transcript expression increases during bradyzoite development.  
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I. T. gondii converts between life cycle stages to propagate and 
transmit  
 
A. Life cycle  
T. gondii is an obligate intracellular protozoan parasite that converts 
between three stages in its life cycle: the sporozoite (contained within the 
oocyst), the tachyzoite (replicative stage inside host cells), and the bradyzoite 
(contained within the tissue cyst). The definitive host of the parasite in which it 
completes sexual replication is the cat (3). The sexual cycle in the cat produces 
oocysts that are shed from cat feces in oocysts. In intermediate hosts, which can 
be any warm-blooded animal (2), T. gondii differentiates between its two asexual 
stages, the tachyzoite and the bradyzoite (Figure 1).   
Oocyst development begins in the intestinal epithelium of the cat (3). Cats 
acquire the parasite from ingesting oocysts in its environment or tissue cysts 
containing bradyzoites. Once in the cat, tissue cyst bradyzoites or oocyst 
sporozoites invade the feline gut and commence replication, undergoing an 
asexual replication phase followed by sexual replication (2, 3). The appearance 
of oocysts depends on the form of the parasite ingested; for example, oocysts 
are excreted in just a few days in cats fed tissue cysts, in about a week in cats 
fed intracellular or free tachyzoites, and 20-24 days in cats fed feces from an 
infected cat (3).  
After feline ingestion of tissue cysts, stomach and small intestine 
proteolytic enzymes dissolve the cyst wall, releasing bradyzoites that invade 
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epithelium along the entire length of the feline intestine (4). Asexual stages 
appear as early as 12 hours post-ingestion and develop sequentially as five 
morphologically distinct types designated A through E (4, 5). Sexual stages 
appear subsequently 3-15 days post-ingestion, coinciding with the late asexual D 
and E stages (4). The mature male sexual stage, termed the microgamont, 
swims to and fertilizes macrogametes to form zygotes. The development of 
zygotes into the oocyst is accompanied by formation of a wall at the surface of 
the zygote. Oocysts are released into the intestinal lumen when the infected 
intestinal epithelium ruptures (5).  
 The number of oocysts a cat sheds following ingestion of bradyzoite cysts 
is in the millions, and intermediate hosts may acquire these oocysts through 
ingestion (6). Digestive enzymes of the intermediate host gastrointestinal tract 
rupture the oocyst wall, releasing the sporozoites within. These sporozoites 
transform into tachyzoites, which invade the small intestine, disseminating in the 
bloodstream to various tissues before converting into the bradyzoite cyst form (5, 
7). Subsequently, the bradyzoite cysts remain latent. They may be further 
transmitted to other intermediate hosts through carnivorism or can reactivate 
spontaneously to cause focal and systemic disease in human patients (2).  
 
B. Transmission 
A major reason behind the widespread prevalence of T. gondii is its ability 
to transmit through multiple routes. The parasite can be transmitted between its 
definitive host (the cat) to its intermediate hosts, which include any warm-blooded 
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animal, and vice versa (Figure 1). In addition, transmission occurs both 
horizontally and vertically in humans, who can contract any of the infectious 
forms of T. gondii (2):    
A. Oocysts distributed from cat excrement into the environment (2) 
B. Bradyzoite tissue cysts in uncooked, raw meat or animal viscera (2) 
C. Tachyzoites in organ transplants, blood products and unpasteurized dairy 
products (2) 
D. Tachyzoites transplacentally in the case of congenital toxoplasmosis (2) 
Toxoplasmosis in the fetus can be contracted when a pregnant woman 
becomes infected with T. gondii as a primary infection (2, 8). Exactly how the 
parasite infects the developing fetus is unknown, although it’s possible the 
parasite invades and replicates in the placenta (9). Congenital toxoplasmosis 
represents only a small percentage of all acquired T. gondii infections (2). Other 
patient populations include those receiving organ transplants and 
immunocompromised patients (10). Patients receiving heart, kidney, liver or bone 
marrow transplants may acquire both the bradyzoite and free tachyzoite form 
residing in the donor organ (11). In immunocompromised patients whose altered 
immune response fails to control the parasite, toxoplasmosis can arise from 
reactivation of latent tissue cysts acquired from a previous infection (10). 
Encephalitis and disseminated disease are common presentations for these 
patients (10). Immunocompromised patients may also contract severe disease 
from primary infection (10). The clinical presentation of the patient populations 
affected by severe T. gondii disease will be reviewed in a later section.  
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The major route by which healthy individuals acquire the parasite is 
through ingestion of oocysts or bradyzoite tissue cysts (2). Tissue cysts can be 
found in common livestock animals such as pigs, sheep and goat, and less 
frequently in poultry (13, 14). In consuming pork, lamb, poultry and other meats, 
humans can limit the risk of ingesting tissue cysts by thoroughly cooking their 
food (2). 
 
 
  
Figure 1. Common transmission routes of T. gondii in intermediate hosts. 
T. gondii undergoes its sexual replicative cycle in the intestinal tract of its 
definitive host, the cat. Cats shed oocysts containing sporozoites. Oocysts can 
be acquired by intermediate hosts such as common consumed livestock via 
contaminated feed. In these intermediate hosts, sporozoites from the oocysts 
transform into tachyzoites that convert into tissue cysts, which can be acquired 
by the definitive host or humans consuming undercooked or raw meat. T. 
gondii can also be passed congenitally to the fetus by the mother, who may 
have ingested tissue cysts in undercooked or raw meat or oocysts from 
changing the cat litter box. Adapted from "Toxoplasmosis Life Cycle". 
Nursingpharmacology.info. 2017. Web. 4 Jan. 2017.   
6 
C. The host immune response  
Innate and adaptive immunity overview 
Most studies of the T. gondii-host immune interaction have been 
performed in mice. However, studies employing human cell lines or patient data 
suggest that parallels exist between mice and human models of the immune 
response to T. gondii. First, in both mice and humans, IFN-γ has been shown to 
be a major lymphokine in the killing of the parasite (15-17). IFN-γ was shown to 
be the component from lymphoid supernatant collected from human 
macrophages stimulated with T. gondii antigen (18). This fraction enhanced 
human macrophage ability to secrete H2O2 and to kill T. gondii tachyzoites, and 
both H2O2 secretion and toxocidal activity was abolished by anti-IFN-γ (18). 
Consistent with these findings showing the essential role of IFN-γ in macrophage 
antimicrobial ability, macrophages isolated from AIDS patients stimulated with 
lymphokine fractions containing IFN-y secreted H2O2 and inhibited T. gondii 
replication, and these effects were again abolished by treatment with IFN-y 
antibody (19).  
In mice, immune control of acute T. gondii infection employs the IL-
12/IFN-γ axis. It was shown that in IFN-γ knockout mice, survival was 
significantly reduced, however IL-12 production was not (20). However, inhibition 
of IL-12 with anti-IL-12 ablated the ability of natural killer cells to produce IFN-
gamma (21).  Injection of IL-12 into mice in early acute infection enhanced mice 
survival (22). Together, these results suggest that IL-12 precedes and initiates 
INF-y production. In response to T. gondii antigen, human innate immune cells 
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such as neutrophils and dendritic cells also release IL-12, although the specific 
subsets of dendritic cells that release IL-12 upon parasite exposure differ from 
mice (23).  
Much remains unknown about how human immune cells recognize T. 
gondii. In mice, a fraction from a T. gondii lysate that induced IL-12 release from 
dendritic cells was further separated, resulting in the identification of profilin, a 
protein involved in actin reorganization during parasite invasion of host cells (24). 
Mice lacking toll-like receptor (TLR) 11 or 12 failed to induce IL-12 release in 
response to profilin stimulation, suggesting that T. gondii recognition relies on 
TLR11 and TLR12 (25-27). However, the gene for TLR11 in humans does not 
encode a functional protein and TLR12 is entirely absent in the human genome 
(28).  In addition, heat-killed tachyzoites failed to elicit cytokine release from 
human monocytes and dendritic cells (29). Therefore, while the detailed 
mechanisms of how human immune cells recognize T. gondii are unknown, they 
most likely occur independently of TLR11/TLR12/profilin system and involve live 
tachyzoites (30).   
 Both humoral and cellular immunity play important roles in the immune 
reaction against T. gondii, and cellular immunity involves both CD4+ and CD8+ 
T-cells (31, 32). Human CD4+ and CD8+ cytotoxic T-cells were isolated from a 
patient chronically infected with T. gondii, and both T-cell populations exhibit 
cytotoxicity to T. gondii-infected cells (33). T. gondii-infected antigen presenting 
cells elicited proliferation of human CD4+ cells as well as generation of specific 
CD8+ memory cells (34). Compared with the role of CD8+ cells, the role of CD4+ 
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may be mostly supplemental and synergistic, as treatment of mice with anti-
CD4+ caused no significant changes in mortality or reactivation (32, 35-37).   
Immune inducers of bradyzoite conversion 
 The release of nitric oxide, stimulated by IFN-γ signaling, is critical for 
reducing parasite replication and inducing the expression of bradyzoite antigens 
(38, 39). The role of nitric oxide in bradyzoite conversion supersedes that of IFN-
γ as nitric oxide is sufficient to induce the conversion, while culturing of certain 
cell types with IFN-γ fails to induce bradyzoite antigen expression (39-41). 
However, IFN-γ is required for maintaining parasite latency, as inhibition of IFN-γ 
with antibody to this lymphokine results in reactivation of cysts and development 
of toxoplasmic encephalitis (42).  
 
D. Toxoplasmosis  
Healthy adults 
 Immunocompetent adults who are able to produce normal immune 
responses to T. gondii are usually asymptomatic (43). About 10-20% of acutely 
infected adults will develop flu-like symptoms, including muscle aches and pains 
and swollen lymph nodes; these symptoms can resolve without treatment within 
weeks to months (43, 44). The incubation period after consumption of meat 
contaminated with tissue cysts is 10 to 23 days and 5 to 20 days after exposure 
to oocysts (45).   
T. gondii is one of the most common causes of posterior inflammation of 
the uvea in immunocompetent hosts. Acute T. gondii infection in the eyes of 
9 
immunocompetent adults may manifest as inflammation of the retina at one focus 
with subsequent involvement of the choroid (46). Eye involvement is usually 
unilateral (46). On clinical inspection, the eye presents an area of focal retinal 
necrosis adjacent a choroidal scar (47).  
Congenital toxoplasmosis 
For the United States, it is estimated that about 400-4,000 cases of 
congenital toxoplasmosis occur annually (48). Congenital toxoplasmosis occurs 
when the parasite crosses the placenta to the developing fetus. Prior infection 
resulting in congenital toxoplasmosis usually occurs in the case of immune-
compromised women such as HIV patients (8). Otherwise, infection of the fetus 
generally only occurs when a woman contracts a primary infection during 
gestation (8). The pregnant woman can contract toxoplasmosis through ingesting 
raw or undercooked meat or in handling cat excrement (such as through 
changing the cat litter box) (49). The infection is usually asymptomatic for the 
woman during pregnancy but can cause miscarriage, stillbirth, or severe 
symptoms in the newborn (8, 50). Around 30% of women transmit primary-
acquired toxoplasmosis to their fetus. The risk of transmission is lowest during 
the first trimester of pregnancy, with a rate of 10-15%. The rate of vertical 
transmission in the second trimester is 25% and is highest during the third 
trimester, at a rate of 60-90% (51). Disease severity in the fetus correlates with 
earlier infection (52).  
The majority of infants with congenital toxoplasmosis will present with eye 
disease, brain calcifications, and hydrocephalus; 61% of patients presenting 
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concurrently with all three signs (53). Other signs the newborn may present with 
include epilepsy and developmental delays (53). Some infants are asymptomatic 
at birth, but develop neurological deficits or developmental disabilities later in life 
(54).   
Acute toxoplasmosis infection might be suspected in a pregnant woman if 
she is immune-compromised or if ultrasound demonstrates findings such as 
hydrocephalus, intracranial calcifications or fetal development abnormalities. 
Diagnosis of acute infection in the woman is based on T. gondii IgG and IgM 
antibody titers (54, 55). Elevated IgG antibody levels indicate that infection by T. 
gondii had occurred in the past, although the exact time of occurrence is 
unknown (56, 57). Elevated IgM antibody levels indicate acute infection (57). 
Because diagnosis of acute toxoplasmosis in a pregnant woman will influence 
pregnancy treatment and even termination decisions, extra care is given to 
validate diagnosis results. Unfortunately, IgM antibody tests are complicated by 
false positives; therefore, specific blood re-testing and antibody avidity test 
guidelines are given to pinpoint diagnosis (58). If a pregnant woman is found to 
be infected with T. gondii during her pregnancy, her fetus will then be tested for 
infection as well. This is accomplished through PCR analysis of amniotic fluid 
(59).  
If a pregnant woman is diagnosed with acute toxoplasmosis, efforts will be 
taken to prevent transmission to the fetus and the patient may be treated with 
spiramycin (56). Fetal toxoplasmosis is treated by switching the woman to 
pyrimethamine and sulfadiazine after the first trimester (56). To protect against 
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bone marrow suppression, one of the side effects of pyrimethamine, folinic acid 
is added to the therapeutic regimen (56).   
Toxoplasmosis in the immunocompromised  
 Severe toxoplasmosis can also occur in humans with compromised 
immune systems. These include patients with HIV/AIDS, hematologic cancers, 
and organ transplant patients receiving immunosuppressive agents. Disease 
initiates from reactivation of latent tissue cysts from prior infection, however 
primary infection may also cause devastating disease in the 
immunocompromised (2, 10). For seropositive AIDS patients who have CD4+ T 
cell count of less than 100 cells/uL, the rate of reactivation can be up to 30% 
(60). Most commonly, infected patients exhibit symptoms such as headaches, 
seizures, ocular inflammation, and focal neurological defects (10). On autopsy, 
“space-occupying lesions” and abscesses in the brain are often found (10). The 
parasite also commonly targets the lung and the heart, causing pneumonitis and 
myocarditis (61). Left unrecognized or untreated, the infection is usually fatal 
(61).  
 Treatment consists of an initial therapy to limit the acute infection, then 
secondary therapy to prevent against recurrence (62). The therapies consist of 
sulfadiazine and pyrimethamine to target the parasite, with lower dosages 
administered for the secondary therapy (62). Folinic acid is added to guard 
against pyrimethamine-induced bone marrow suppression (63). Prophylactic 
therapy is necessary for as long as the patient is immune-compromised, because 
the drugs do not target the latent tissue cysts, which may reactivate (62).  
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Toxoplasmosis in organ transplant patients 
 Toxoplasmosis may affect patients receiving either solid organ transplants 
or hematopoietic stem cell transplants (11). In solid organ transplant recipients, 
disease usually results from transmission of the tissue cysts through the donor 
organ and reactivation of these cysts in the recipient who is receiving 
immunosuppressive therapy, while in hematopoietic stem cell patients, the cause 
of toxoplasmosis is usually from reactivation of a pre-existing, latent infection in 
the recipient (11). The major clinical signs associated with transplant 
toxoplasmosis include pneumonitis and encephalitis, often with dissemination to 
multiple organ systems (11).  
 Diagnosis of toxoplasmosis by serology is often difficult in organ transplant 
patients who usually present with an altered immune status. Diagnosis therefore 
relies on confirming the presence of the parasite such as through PCR analysis 
or microscopic examination of bone marrow aspirates, bronchoalveolar lavage, 
and tissue biopsies (64).  
 For hematopoietic stem cell recipients who are seropositive for antibodies 
to T. gondii or for seronegative solid organ recipients receiving from a 
seropositive donor, prophylaxis before the transplant procedure is recommended 
to guard against reactivation disease (64). In this case, co-trimoxazole is the 
preferred therapy in the United States (64). 
Current drug therapeutics for T. gondii 
 The first-line drug therapy for patients with T. gondii infection (including 
women with acute T. gondii infection, infants with congenital toxoplasmosis, 
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AIDS and other immune-compromised patients who develop toxoplasmic 
encephalitis, or patients with ocular toxoplasmosis) is pyrimethamine and 
sulfadiazine (65). Leucovorin is usually added to the therapy regimen because it 
protects against bone marrow suppression (65). Clindamycin may be substituted 
for sulfadiazine if the patient is allergic to sulfa drugs, and the pyrimethamine 
plus clindamycin regimen has been shown to be equally efficacious as 
pyrimethamine plus sulfadiazine for AIDS patients with toxoplasmic encephalitis 
(65, 66). The trimethoprim-sulfamethoxide combination can be used if 
pyrimethamine is not available and if patients do not have allergies to 
sulfamethoxide, another sulfa drug; no differences in clinical response to either 
drug combination was detected in HIV patients with toxoplasmic encephalitis 
(67).  
Pyrimethamine, sulfadiazine, trimethoprim, and sulfamethoxazole are 
compounds that act on separate steps in the folic acid metabolism pathway (68). 
Sulfadiazine and sulfamethoxazole are competitive inhibitors of dihydropterate 
synthetase, and pyrimethamine and trimethoprim inhibit dihydrofolate reductase 
(68-70). Clindamycin has been demonstrated to reduce protein synthesis and 
inhibit parasite replication at low concentrations in mouse macrophage cultures, 
with 50% inhibitory concentration of 32.50ug/mL (71). Leucovorin, used to rescue 
bone marrow suppression, is a reduced form of folic acid that can be converted 
into tetrahydrofolate without DHFR, thus bypassing the blockage of 
tetrahydrofolate synthesis during pyrimethamine inhibition of dihydrofolate 
reductase (69).   
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E. Genetic lineages of T. gondii and toxoplasmosis  
Strain isolates of the parasite from Europe or the USA group into three 
main lineages based on genotype analysis (72). However, genotypes not 
belonging to the three main lineages exist and appear to be attributed to higher 
genetic variations and recombination among these parasite groups, which are 
found outside Europe and North America such as in Africa and South America 
(73, 74). The three main lineages that are predominant isolates from Europe or 
the USA are designated Type I, II and III and were classified based on restriction 
fragment length polymorphism (RFLP) analysis of six different T. gondii genetic 
loci (75). The analysis also revealed that these lineages are >95% similar, 
suggesting clonal population structure and an absence of random mating (75). 
Despite this degree of genetic similarity, the three lineages differ in their 
epidemiological prevalence in human toxoplasmosis and also exhibit clear 
phenotypic differences when studied in mice models of acute and chronic 
infection (75-78). Of clinical importance, type II isolates were found to 
predominate human toxoplasmosis. Type III strains are common in animals and 
significantly less observed in human disease cases (75). An assay consisting of 
PCR amplification followed by RFLP of the SAG2 locus was subsequently 
developed and used to classify parasite samples isolated from toxoplasmosis 
patients (77). The SAG2 assay revealed that 81% of strains isolated from patient 
samples were grouped as type II, further buffeting the observation that the 
majority of human disease is caused by type II strains of T. gondii (77).  
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In mice models of acute infection, the three lineages segregate strongly 
into virulent and non-virulent strains (75-78). The distinction for virulence is 
based on 100% lethal dosage in outbred Swiss mice, with “virulent” strains 
exhibiting LD100 < 10 and “non-virulent” strains exhibiting LD100 > 1000 (78).  
Type I strains (i.e. RH, GT1, OH3, PT, and ENT isolates) which are highly 
virulent lead to systemic dissemination and death of mice within ten days in mice 
following inoculation of less than ten parasites (78, 79). Type II (ME49, 
Prugniaud) strains exhibit intermediate virulence compared to the low virulence 
of type III strains like VEG (78). The genetic loci responsible for the virulence 
differences between the three lineages is a topic of intense interest, with new 
“virulence factors” revealed through forward and reverse genetic approaches 
through the years (80, 81). These mediators of acute virulence appear to 
modulate the host immune response (81).  
Differences in strain virulence can be mapped to genetic variation in SAG1 
alleles (78, 82). Comparison of the lengths of restriction digest fragments of 
SAG1 revealed specific patterns to mouse-virulent versus mouse-avirulent 
strains (78). Subsequent analyses of SAG1 revealed seven nucleotide 
mismatches between mouse-virulent and mouse-avirulent strains occurring in the 
322-bp region upstream of the AUG start codon (82). In addition, mouse-avirulent 
strains lacked one stretch of 27-bp repeats found in the this upstream region, 
such that mouse-virulent strain contained five of these repeats compared to four 
in the mouse-avirulent strain (82). Finally, transcript expression of SAG1 was at 
least four-fold higher in the mouse-virulent strain (82). These results suggested 
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that SAG1 is a factor contributing to virulence differences between the three 
prominent T. gondii lineages (78, 82).  
Besides virulence, other traits such as tissue cyst-forming rate, host 
mitochondria association, and gene expression differ between strains. Strains 
exhibiting lower virulence in mice produce higher numbers of cysts compared to 
the higher virulence strains (83, 84). There is a correlation between the strain 
replication rate and its cystogenic rate; for example, Type II and Type III strains 
exhibit lower replication rates and form higher numbers of cysts (85).  
 Host mitochondria association (HMA) has been observed in organisms 
besides T. gondii, such as in L. pneumophila and C. psittacci (86, 87). The 
functional consequences of HMA in these organisms is not understood, but 
pathogens such as hepatitis C virus and H. pylori manipulate host mitochondria 
to induce specific immune responses or cellular apoptosis (88, 89). Examination 
for HMA using Mitotracker in human foreskin fibroblasts (HFFs) infected with 
either Type I RH, Type II ME49 or Type III CEP strains revealed that while 
association of host mitochondria at the parasitophorous vacuole membranes 
(PVMs) of RH and CEP strains was observed, this was not the case for ME49 
(90). The experiment was repeated with Type II Pru strains, which also 
demonstrated absence of HMA as well as significantly lower expression of the 
gene MAF1 discovered to mediate HMA (90). The exact reason for this strain-
specific difference is currently unknown. Since it has been shown that host 
mitochondria-pathogen interaction can modulate immune signaling in some host-
pathogen systems, and since there are strain-specific differences in cytokine 
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release, the role of T. gondii HMA in immune signaling is possible (91, 92). 
Together, these observations provide examples of strain-specific phenotypes 
which can possibly impact the pathogen-host interaction.     
 Type II and Type III strains exhibit higher efficiency tissue cyst formation in 
vitro and in vivo (83-85). This observation has been correlated with the 
hypovirulence of these strains compared to Type I, their lower replication rates, 
and specific gene expression patterns in these strains (83-85, 93). Differences in 
the specificity and expression levels of genes between Type I, Type II, and Type 
III parasites were implicated in a comparison of SAGE tag libraries from Type I 
RH, Type II ME49 and Type III VEGmsj parasites (93). The identity and 
expression levels of genes between each strain as compared to libraries from 
different timepoints of the sporozoite-to-bradyzoite development pathway (93). 
The Type I RH library was most similar to Day-6 post-sporozoite infection 
parasites, which have emerged from sporozoite-infected cells, re-invaded and 
are rapidly replicating. In contrast, the Type II and Type III libraries exhibited 
basal levels of bradyzoite markers such as ENO1 and Sag4.2, which are not 
detected in the Type I RH library (93). While the basal bradyzoite expression may 
be a result of a subpopulation of differentiated Type II and Type III parasites, 
these results are consistent with the observation that Type II and Type III strains 
are more efficient at bradyzoite differentiation (83-85).  Consistent with these 
findings, Saeij et. al found an apparent inverse relationship between strain 
virulence and bradyzoite gene expression when examining the gene expression 
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and growth rate of an avirulent and virulent progenitor from a Type II and Type III 
cross (94).  
 
II. The bradyzoite is important to transmission and pathogenesis 
 
A. Structural morphology of bradyzoite cysts 
Bradyzoites are contained in the host cell inside a modified 
parasitophorous vacuole, which is bound by the parasitophorous vacuole 
membrane (PVM) derived from the plasma membrane of the host (83). Early 
electron microscopy of a type II T. gondii strain revealed that cyst wall material is 
deposited gradually at the membrane, with early cysts showing patchy 
aggregation and mature cysts showing a continuous thick wall (83). Specifically, 
the cyst wall material is a “dense granular precipitate” found scattered between 
bradyzoites, leading the authors to believe the granular matrix is parasite-
secreted (83). The composition of the cyst wall is now believed to contain both 
parasite-derived and host-derived components. Staining of the cyst wall with 
protargal silver, in a protocol used to detect neuronal-specific elements, 
suggested that the walls of neuronal cysts are composed in part of host cell 
constituents (95). 
Studies on the composition of the cyst wall suggest that this structure is 
composed of specific polysaccharides and glycosylated proteins. The walls stain 
with specific lectins, carbohydrate-binding proteins derived from plants. In one 
study, only two lectins out of twelve tested were able to bind the bradyzoite cyst 
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wall (96). These were succinylated wheat germ agglutinin (S-WGA), which binds 
N-acetyl-glucosamine (GlcNac)-like residues, and Dolichos biflorus lectin (DBA), 
which binds N-acetyl-galactosamine (96). Dolichos lectin remains one of the 
most common tools to stain cyst walls for the field.  
The bradyzoite cyst wall also binds Concanavalin A (Con A), a lectin that 
specifically binds D-mannose or D-glucose-like residues and soy bean agglutinin 
(SBA), which binds N-acetyl-galactosamine-like residues (97). In addition, the 
composition of the cyst wall may be similar to chitin, a major cell wall component 
in yeast. GlcNac polymers are a constituent of chitin, a yeast cell wall protein, 
and treatment with chitinase disrupted both the integrity of the cyst wall and S-
WGA binding (97). 
The protein CST1 is a major constituent of the bradyzoite cyst wall. 
Electron micrographs show that this protein is localized to the PVM (98). CST1 is 
responsible for the majority of Dolichos biflorus lectin binding, as immunoblotting 
of a 2D gel with CST1 with DBA resulted in a detectable single band at 116 kDa, 
the size of CST1. Knocking out CST1 resulted in near-complete loss of DBA 
binding (99). CST1 was not essential for cyst formation, but is important for 
structural integrity of the cyst wall as its deletion resulted in fragile cysts that 
ruptured easily (99).   
In addition to CST1, the cyst wall is composed of proteins released by 
secretory organelles called dense granules (100, 101). These dense granule or 
“GRA” proteins include nearly the entire repertoire as that found for tachyzoites 
(100, 101) and localize to the parasitophorous vacuole. However, the sizes of 
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these proteins may differ between stages, possibly due to modifications such as 
glycosylation. In support of the possibility that the same protein product is 
differentially modified between the stages, a monoclonal rat antibody recognizes 
a 40kDa antigen in the tachyzoite stage and a 115 kDa antigen in the bradyzoite 
stage (102). 
The importance of secreted proteins in forming the bradyzoite cyst wall 
prompted screens for proteins secreted during the bradyzoite stage. A list of 
genes that are differentially expressed between the tachyzoite and bradyzoite 
stage was obtained from transcriptomic analysis of the M4 Type II strain. This list 
was then narrowed to those with putative signal peptides (103). Two genes – 
bradyzoite pseudokinase 1 and microneme-adhesive repeat containing protein 4 
(MCP) – were tested and confirmed for their localization at the PVM (103). While 
the specific function and localization of the majority of these putative secreted 
proteins is unknown, the screen expands the catalogue of potential cyst wall 
constituents.  
 
B. Inducers and molecular changes of bradyzoite differentiation 
Tachyzoites convert to bradyzoites in a process called bradyzoite 
differentiation. While immune modulators such as IFN-γ and IL-12 induce this 
process, in vitro methods are able to induce the expression of tissue cyst 
markers. In 1994, Soete et al. identified several in vitro conditions that induce the 
expression of bradyzoite antigens (104). The authors subjected RH tachyzoites 
to several stress conditions, including alkaline pH, incubation at high 
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temperatures (43⁰C), sodium arsenite (a chemical stress inducer) and IFN-γ 
(104). In their experiments, with exception of IFN-γ, all of these stress conditions 
were effective at inducing bradyzoite antigen expression (104). Alkaline pH (pH 
8.0-8.2) remains one of the most convenient and effective in vitro inducers of 
bradyzoite differentiation for the field. Induction of bradyzoite-specific antigens is 
also triggered by application of sodium nitroprusside to parasite cultures; sodium 
nitroprusside acts as an exogenous source of nitric oxide (38). The mechanism 
of nitric oxide is supposedly binding to iron-sulfur clusters in mitochondrial 
electron transport chain proteins, inhibiting their function (38). Other drugs that 
interfere with mitochondria function, such as oliqomycin A and atovaquone, also 
trigger bradyzoite differentiation (38, 105).  
As discussed earlier, the relative frequency of differentiation depends on 
the T. gondii strain, where slower-replicating and lower virulent strains such as 
ME49 exhibit a higher differentiation frequency compared to fast-replicating 
virulent strains such as RH (83-85, 104, 106). These observations are consistent 
with those demonstrating a longer G1/S cell cycle length for slower-replicating 
strains and that a decrease in growth rate precedes bradyzoite differentiation (38, 
107, 108). In summary, bradyzoite differentiation is accompanied by a decrease 
in parasite replication rate.  
Bradyzoite development and relationship to the tachyzoite cell cycle 
 Initiation of bradyzoite development is accompanied by reduced parasite 
replication (38). This is observed in treatment of tachyzoites with all the classic in 
vitro bradyzoite inducers, including alkaline pH, nitric oxide, and mitochondrial 
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inhibitors. Molecular dynamics of the cell cycle are clearly important for 
bradyzoite development, as cell cycle arrest precludes bradyzoite differentiation 
(107). Furthermore, analysis of differentiating parasite populations reveals an 
enrichment for parasites in the S/M phase of the tachyzoite cell cycle. For 
example, an increase in the number of parasites with 1.8-2N amount of nuclear 
DNA accompanies the appearance of BAG1 antigen in alkaline-treated parasites, 
concomitant with a decrease in parasites in the M/C phase (108). Furthermore, 
the population of parasites containing the 1.8-2N amount of DNA is both positive 
for SAG1 and BAG1, suggesting parasites at the onset of the tachyzoite-to-
bradyzoite transition (108). Supporting the view that the S/M boundary is 
important for the commitment to bradyzoite differentiation, peak expression of 
bradyzoite transcripts during the tachyzoite cell cycle occurs at this phase 
boundary (109). Therefore, although the molecular events are not clearly 
understood, it is evident that bradyzoite differentiation is associated with the S/M 
phase of the tachyzoite cell cycle. To fully understand how the tachyzoite cell 
cycle and bradyzoite development are linked, the function and mechanism of cell 
cycle-regulated molecular players involved in bradyzoite differentiation should be 
identified. Of interest are those transcriptional factors with peak expression 
around the S/M boundary, which possibly play a role in the commitment to 
bradyzoite differentiation.  
Upregulation of stress responses 
In response to stress such as high pH, T. gondii launches a common 
environmental stress response (ESR) characterized by upregulation of genes 
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involved in detoxification, metabolism (ie. glycogen and trehalose synthesis), 
protein folding and degradation, and oxidative protection and mitochondrial 
function (110). Specifically to alkaline pH, T. gondii also upregulates PHO84, a 
member of the phosphate transport and metabolism family that is upregulated in 
yeast as a response to alkaline stress.  
Through the years, a number of “bradyzoite-specific” genes have been 
characterized for their function in stress response. Screening of a bradyzoite 
expression library with bradyzoite-specific monoclonal antibody mAB 7E5 
identified a ~30 kDa protein that shared homology with plant small heat shock 
proteins (111). This protein is now annotated as HSP30 or BAG1 (111). BAG1 
polyclonal antiserum reacted only to bradyzoite but not to tachyzoite lysate, 
suggesting that this protein is bradyzoite-specific (111). As a bradyzoite-specific 
antigen, BAG1 remains an important marker of differentiation for the field. BAG1 
is induced by day three of bradyzoite induction and is localized to the bradyzoite 
cytoplasm (111). Another heat shock protein, DnaK-TPR, is also bradyzoite-
specific, and yeast-two hybrid screening revealed this protein interacted with a 
co-chaperone protein, suggesting a role for this protein as a molecular 
chaperone (112).  
In both higher eukaryotes and in yeast, stress conditions result in the 
phosphorylation of serine 51 of eIF2α, which then inhibits its guanine nucleotide 
exchange factor eIF2B (113). This precludes the methionine-tRNA charging 
ability of eIF2A, leading to a global decrease in translation. A protein homologue 
of eIF2α was cloned in T. gondii and demonstrated to be phosphorylated at 
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serine 51 under different bradyzoite-induction conditions, including heat shock, 
alkaline pH, tunicamycin and sodium arsenite (114, 115). TgIF2α phosphorylation 
was accompanied with a global decrease in translation initiation in parasites 
treated with tunicamycin (115). Bradyzoites exhibit significantly higher levels of 
TgIF2α phosphorylation compared to unstressed tachyzoites (115). Furthermore, 
inhibition of dephosphorylation by treating parasites with salubrinal resulted in 
induction of bradyzoite genes (115). These observations suggest that 
translational control plays an important role in bradyzoite differentiation, which is 
accompanied by a global reduction of protein translation. As in higher eukaryotes 
where different eIF2α kinases phosphorylate eIF2α under different stress 
conditions, separate eIF2a kinases haveα been cloned in T. gondii (114). 
TgIF2K-A localizes to the T. gondii endoplasmic reticulum while TgIF2K-B 
localizes in the cytosol (114). Therefore, the translational reduction conserved in 
higher and lower eukaryotes under stress conditions also accompany bradyzoite 
development.  
 
C. Gene expression changes accompanying bradyzoite development 
A number of transcriptome approaches have been undertaken to 
understand the gene expression changes accompanying bradyzoite 
development. One of the earliest explorations into the bradyzoite transcriptome 
utilized sequencing a library of expression sequence tags (ESTs) generated from 
ME49 bradyzoite cysts in chronically infected mice (116). Comparison of the 
bradyzoite cDNA sequences to a parallel tachyzoite library identified a set of 
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genes restricted to the bradyzoite stage. However, this EST sequencing 
approach had limitations since it did not measure transcript abundance or timing 
of expression. To solve this problem, Cleary et al. constructed microarrays, using 
DNA derived from the bradyzoite EST library for spotting the arrays (117). This 
approach identified developmentally regulated genes that were either induced or 
repressed in bradyzoites compared to tachyzoites. Comparison of transcript 
levels from two-, three- and four-day in vitro bradyzoite to tachyzoite cultures 
allowed identification of those bradyzoite transcripts that were “induced, 
constitutive, or repressed” relative to tachyzoite transcripts (117). Novel 
developmentally regulated genes such as SRS9 (induced in the bradyzoite) and 
rhoptry protein 1 and 4 (repressed) were also revealed (117).   
Finally, it was evident that induction of bradyzoite transcripts occurs in a 
temporal fashion (117, 118). For example, BAG1 and enolase 1 (ENO1) were 
classified as “mid-late” genes as their transcripts expression relative to that in 
tachyzoites did not peak until day four post bradyzoite-induction (117). In 
contrast, other genes such as lactose dehydrogenase 2 (LDH2) were expressed 
from day two through day four of the experiment, suggesting that LDH2 
expression may be induced as early as day two post-induction (117).  
 Gene expression changes accompanying the tachyzoite-to-bradyzoite 
conversion were further assessed in 2005 by Benhke et al. (119). In addition to 
demonstrating the existence of developmentally regulated genes, this study 
demonstrated that these genes are regulated in cohorts (119). In other words, 
transcripts are expressed through the cell cycle with a “just-in-time” control. 
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Clearly, a mechanism exists that allows for both specific and temporal timing of 
gene expression in parasite replication and development.  
In part, gene expression changes accompanying stage conversion can be 
explained by the dynamic nature of chromatin remodeling and association of 
epigenetic complexes. In the T. gondii genome, the players for epigenetic 
modulation are readily present and include histone acetyltransferases (HATs) 
from the GCN5 and MYST families (120, 121), histone deacetylases (HDACs) 
and histone arginine methyltransferase (122) and chromatin remodeling 
complexes such as those from the SWI/SNF family (123). Furthermore, 
epigenetic marks follow stage-specificity. The tachyzoite stage is marked by 
hyper-acetylation at tachyzoite-specific genes such as SAG1 and SAG2A and a 
hypo-acetylation at bradyzoite-specific genes such as BAG1 and LDH2 (122). In 
the bradyzoite stage, these acetylation patterns are reversed, with a hyper-
acetylation of promoters at BAG1 and LDH2 and hypo-acetylation of promoters 
at the tachyzoite-specific genes.  
 
D. T. gondii cis-regulatory elements  
In other species, gene expression is modulated by transcription factors 
that bind to specific motifs called cis-regulatory elements upstream of the coding 
sequence. Stage-specific cis-regulatory elements have been shown to exist in T. 
gondii. Promoter mapping experiments have been undertaken for the purpose of 
expression control in transgenic parasites, understanding developmental 
switches, and understanding basic cis-regulatory sequences controlling 
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transcription. Promoter truncation demonstrated that the motifs essential for 
SAG1 expression consist of six 27 bp repeats with no requirement on their 
orientation and dictate the location of the transcriptional start site. In addition, 
these repeats were sufficient to induce expression from a heterologous promoter 
(124). Truncation mutations with the 5’ regions of the NTP 1, 2 and 3 genes 
identified the approximate upstream bp region necessary for expression (125). In 
addition, deletion of a segment of the NTP3 5’ region altered downregulation in 
the bradyzoite stage, suggesting transcriptional elements regulate stage 
expression for NTP3 (125). Both SAG1 and NTP upstream lacked a canonical 
TATA box; with NTP3 it was shown an initiator-element (Inr) consensus was 
necessary for basal expression (125). The pH 8-inducible expression of hsp70 
has been mapped to a 70bp region which was shown to be sufficient for 
increased pH 8 induction using GFP reporter construct (126). This 70bp cis-
regulatory element was the first to be shown to be able to bind with a protein in a 
T. gondii lysate, assumed to be a putative transcription factor (126). Interestingly, 
homologies to the 70bp region was not found for hsp60 and hsp90, suggesting 
unique promoter motifs exist for bradyzoite-specific gene expression (126). The 
promoter mapping for dihydrofolate thymidylate synthase emphasized the 
importance of GC-rich regions upstream of the transcriptional start site (127). 
Such GC-rich regions were also found in the BAG1 promoter. 
First, the 324 base pairs immediately upstream of the BAG1 initiation 
codon were demonstrated to be essential for induction of expression (128). 
Another study further fine-mapped the promoter region for BAG1 to the 
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nucleotide motif TACTGG required for expression (129). Fine-mapping was also 
accomplished for the bradyzoite NTPase gene (129). The promoter elements 
were sufficient to induce the expression of bradyzoite genes under both 
Compound 1 and alkaline pH, suggesting that bradyzoite expression is activated 
through common promoter sequences (129). Finally, nuclear extracts applied to 
electromobility shift assays, using the minimal genomic elements required to 
induce bradyzoite gene expression, demonstrated that unspecified nuclear 
factors indeed bind specific promoter motifs (129).  
Therefore in these studies, the upstream sequences of bradyzoite-specific 
genes that contain cis-regulatory sequences were shown to be 1.) necessary and 
sufficient for bradyzoite gene transcription, 2.) able to activate gene expression 
under a variety of bradyzoite induction conditions and 3.) bound by nuclear 
factors. However, the identity of these nuclear factors remained unknown.  
Moreover, the study of the SAG2CDXY promoter demonstrates the 
importance of cis-regulatory sequences in regulating the time course of in vivo 
infection. The SAG2CDXY locus is a cluster of genes encoding bradyzoite-
specific surface markers (130). Tachyzoites containing at truncation of the 
SAG2CD promoter fused to firefly luciferase exhibited bioluminescence levels 
comparable to that in bradyzoites, suggesting that the truncated promoter portion 
may repress the expression of the gene in the tachyzoite stage (130). In addition, 
mice infected with parasites expressing firefly luciferase under the full SAG2D 
promoter exhibited signal starting at day 9 post-infection (130). These studies 
with the SAG2CD promoter demonstrated both a temporal regulation of 
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bradyzoite gene expression and stage-specific control of these genes by possible 
repression in the tachyzoite stage. The in vivo switch of tachyzoites to 
bradyzoites is the first step to establishing chronic infection; identification of 
temporally-regulated specific transcription factors will help illuminate the 
mechanism by which stage-specific gene expression occurs.  
 
III. The ApiAP2s represent a primary lineage of putative transcription 
factors  
 
A. Discovery of the ApiAP2s 
Transcription in both prokaryotes and eukaryotes utilize three basic 
classes of machinery: RNA polymerase II, general transcription factors and 
specific transcription factors. Basal transcription begins with formation of the 
preinitiation complex consisting of RNA polymerase II and general transcription 
factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) that bind core promoters 
proximal to the transcription initiation site (131-133). Enhancement or repression 
of basal transcription occurs via binding of specific transcription factors to cis-
regulatory elements upstream or downstream of the core promoter (133, 134). 
Once a specific transcription factor binds to its regulatory motif, it may recruit the 
preinitiation complex via its transactivation domain or epigenetic machinery such 
as chromatin remodeling enzymes, histone acetyltransferases or deacetylases. 
The specific transcription factor can also modulate basal gene expression by 
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blocking the assembly of the preinitiation complex or activator specific 
transcription factors or blocking the recruitment of HATs (135).  
Based on homology, all three RNA polymerases have been identified in 
the T. gondii genome (136). All twelve subunits of RNA polymerase II, whose 
main role is mRNA transcription, are present (134). Various components of the 
general transcription factors have been located in the T. gondii genome, 
including some but not all subunits of TFIID, TFIIE, TFIIF and TFIIH. TFIIA is 
missing entirely along with most of the TATA-box protein-associating factors 
(136). This suggests that basal T. gondii transcription shares certain mechanistic 
features with higher eukaryotes yet exhibits unique features as demonstrated by 
its simplified or yet unidentified repertoire of general transcription machinery. 
An evolutionarily expanded group of specific transcription factors 
populates the genome of eukaryotes. Major classes are grouped by their 
structure and include the helix-turn-helix class of specific transcription factors, 
consisting of two α-helices connected by a short loop and includes the 
homeodomain and forkhead proteins; the zinc finger factors which is further 
subdivided based on fold groups but are united by coordination of a zinc ion 
within their folds; the basic zipper proteins; and the helical domain proteins which 
include the bZip and basic helix-loop-helix proteins (137). The T. gondii genome 
contains putative DNA-binding proteins belonging to various classes of major 
eukaryotic transcription factors, such as members of the MYB, C2H2 zinc finger, 
HMG1, and AT-hook proteins (138). However, compared to higher eukaryotes, 
expansion of these classes of transcription factors is not observed; animals for 
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example contain more than 100 members of the C2H2 zinc finger factors 
compared to less than ten as annotated in the T. gondii ME49 genome 
(ToxoDB.org). In addition, Apicomplexan genomes reveal a complete lack of 
other members of the major transcription factor classes such as the forkhead, 
basic helix-loop-helix, homeodomain, STAT, retinoblastoma, MADS-domain and 
CENPB proteins (138). This called into question the identity of the primary 
lineage of specific transcription factors for T. gondii. 
Therefore, Balaji et al. in 2005 explored the possibility that the 
predominant specific transcription factors of Apicomplexa were distantly related 
or even unrelated to conserved eukaryotic specific transcription factors. 
Searching for predicted proteins with DNA domains and motifs in the 
Apicomplexan Plasmodium, they focused on a DNA-binding motif called the AT-
hook, which is found in a number of chromosomal proteins (139). Importantly, the 
AT-hook is often associated with larger globular DNA-binding domains. Indeed, 
the AT-hook containing protein also contained a domain which BLAST searches 
revealed to belong to the apetela2 (AP2) class of DNA-binding domains. The 
AP2 domain was discovered to be well-conserved in other Apicomplexa such as 
Theileria and Cryptosporidium (139).  
The AP2 class of DNA-binding domains has been previously 
characterized as developmental transcription factors in plants (137). Structurally, 
the ApiAP2s consist of three strands and a helix that is a conserved backbone 
structure involved in DNA sequence binding. Unlike the plant AP2s, however, the 
ApiAP2s include a hairpin linker structure between two of the strands that is 
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hypothesized to be important for specifying DNA contact (139, 140). The ability of 
several ApiAP2 proteins to bind specific DNA sequences has been validated 
using “protein binding microarrays” or PBMs (142). These arrays are spotted with 
DNA 10-mers, to which a recombinant, tagged AP2 domain is applied (141). The 
structural and functional homology of the AP2s and their ability to bind potential 
cis-regulatory sequences cast the ApiAP2s as the primary lineage of putative 
specific transcription factors for the Apicomplexa. 
 
B. Function of AP2s in plants and in Apicomplexa 
In plants, the AP2s are responsible for proper development and response 
to environmental stress. Mutations in AP2 proteins result in abnormal patterning 
of flower organs, shape of leaf epidermal cells, and plant height (142-144). The 
response of plants to various environmental stresses is mediated by different 
subgroups of AP2s, with the DRE-motif binding transcription factors (DREBs) 
responding to drought and cold and ERF class responding to biotic factors such 
as pathogens (145). Other plant AP2s integrate multiple stress responses 
through triggering crosstalk with other AP2s or forming differential protein 
complexes (146-148).  
A number of Apicomplexan AP2s have been functionally characterized 
and play roles ranging from parasite development to virulence. PfSIP2 was found 
to bind to subtelomeric regions of heterochromatin at the SPE2 motif, a 
conserved sequence hypothesized to be important for silencing of the virulence 
var genes (149). Consistent with the temporal cascade of just-in-time expression, 
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Plasmodium AP2s have been demonstrated to regulate gene expression within 
specific developmental stages, for example, AP2-O binds a specific six-mer DNA 
sequence to activate genes for midgut invasion (150). Expressed in the mosquito 
gut late-stage oocyst and the salivary gland sporozoite, AP2-Sp is essential for 
sporozoite formation and recognizes a specific eight-mer motif to regulate gene 
expression during this stage (151).  
Following injection of sporozoites into the host, the parasites invade liver 
hepatocytes. AP2-L has been identified that is crucial for successful infection of 
the liver; although AP2-L knockout parasites invaded hepatocytes normally, they 
growth-arrested in the schizont stage which precedes merozoite formation (152). 
During their development in the human liver, malarial merozoites must either 
continue replicating asexually or commit to gametocyte production. Recently it 
was shown that nuclear factor PfAP2-G is essential for commitment to the 
gametocyte stage, as null mutants failed to form any gametocytes (153, 154). In 
addition, electromobility shift assays confirmed the ability of PfAP2-G to bind 
specific DNA motifs found upstream of gametocyte development genes (154). 
Transcripts for early gametocyte development were also downregulated in 
PfAP2-G null mutants (154). Together these results demonstrate that PfAP2-G is 
a transcriptional activator of genes involved in the gametocyte stage for 
Plasmodium. Deletion of PfAP2-G2, on the other hand, allows commitment to the 
sexual development stage but precluded complete development of the 
gametocyte (153, 155).  
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C. Function and mechanism of T. gondii AP2s 
Only three of the 68 T. gondii AP2s have been functionally characterized, 
with two (AP2IX-9 and AP2XI-4) identified with roles in bradyzoite development 
(156-158). Since the bradyzoite cyst is essential for pathogenesis and 
transmission, identifying the transcriptional players directing bradyzoite 
differentiation is crucial. Of the 68 T. gondii AP2 proteins, mRNAs of 15 are 
induced during early in vitro bradyzoite development (159), with a subset of these 
also induced at least ten-fold in mouse brain cysts (160).  
AP2IX-9 has been characterized as a bradyzoite repressor (156). It is 
expressed in early but not late in vitro bradyzoites, and ablation of the factor in 
RH and the PLK strain of ME49 resulted in an increased frequency of bradyzoite 
development, suggesting that AP2IX-9 is a repressor of bradyzoite development 
(156). Conditional overexpression of the factor further supported this model, as 
enhancement of AP2IX-9 expression limited bradyzoite cyst formation (156). As 
a putative transcription factor, AP2IX-9 was demonstrated to bind a specific cis-
regulatory element that includes a motif in the B-NTPase promoter (156). It 
directly downregulates the expression of bradyzoite-specific genes such as 
BAG1, LDH2, and ENO1 besides B-NTPase (156). Finally, chromatin 
immunoprecipitation experiments confirmed that AP2IX-9 associates with the 
promoter of BAG1 (156). As a transcriptional repressor of bradyzoite gene 
expression, AP2IX-9 may act to prevent premature commitment to bradyzoite 
development. This might occur to allow the parasite to balance latency with 
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replication when faced with the host immune response or when the parasite 
infects a host tissue unfavorable for differentiation (156).   
While AP2IX-9 has been characterized as a bradyzoite repressor, AP2XI-
4 appears to be a bradyzoite activator (157). AP2XI-4 is expressed in bradyzoites 
in a cell cycle-regulated manner (157). Although its mRNA profile suggests its 
peak expression is between the mitotic and cytokinesis stage of the cell cycle, 
endogenously tagged AP2XI-4 demonstrated robust expression in the 
cytokinesis and G1 phase with minimal expression in S and M (157). No 
significant difference in growth rate was observed between wild-type and AP2XI-
4 parasites (157). However, knockout of this factor resulted in downregulation of 
bradyzoite transcripts, suggesting a role for this factor as an activator of 
bradyzoite expression (153). Mice infected with a knockout strain of AP2XI-4 
subsequently carried five-fold fewer brain cysts compared to mice infected with 
the wild-type (157).  
AP2XI-5 appears to regulate virulence genes during the tachyzoite stage 
of the parasite (158). AP2XI-5 binds preferentially to promoters of genes involved 
in parasite invasion such as rhoptry and microneme proteins (158). A specific cis-
regulatory motif (GCTAGC) was enriched in the chromatin immunoprecipitation 
peaks for AP2XI-5, which was confirmed to bind to the nucleotides 
encompassing this motif upstream of the ROP18 promoter (158).  
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IV. Goals for this thesis 
T. gondii is a prevalent pathogen transmitted in intermediate hosts as the 
bradyzoite tissue cyst. In immune-compromised individuals, these tissue cysts 
may spontaneously reactivate, causing local organ damage and disseminated 
disease. As bradyzoites are crucial for transmission and pathogenesis, they are 
also crucial candidates for drug targeting. Diverse aspects of bradyzoite cellular 
biology have been uncovered, including the general composition of the cyst wall 
and bradyzoite surface antigens, the role of heat shock proteins and translational 
control and the role of epigenetic histone modification in stage switching. 
Transcriptional changes clearly underlie the transition from tachyzoite to 
bradyzoite and identifying the molecular players that regulate these expression 
changes would reveal the mechanism of stage reprogramming. Cis-regulatory 
sequences for tachyzoite- and bradyzoite-specific genes have been identified 
that are essential for complete expression, and proteins in parasite lysate were 
shown to bind several of these cis-regulatory sequences. These observations 
strongly suggest a role for specific transcription factors. However, bioinformatics 
mining of the T. gondii genome had revealed few members of the canonical 
eukaryotic classes of DNA-binding proteins.  
The identification of nearly 70 proteins with ApiAP2 domains suggest that 
this class of DNA-binding proteins may serve as the primary lineage of specific 
transcription factors for T. gondii. Three of these 70 have been functionally 
characterized, with two involved in bradyzoite activation and repression. Novel 
AP2s are ideal candidates to further understanding some of the most important 
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questions remaining for bradyzoite biology. These include mapping the molecular 
networks driving bradyzoite differentiation along with the exact timing of 
transcriptional changes occurring as the bradyzoite develops. Fortunately, stage 
conversion transcriptome data has provided clues to which AP2 factors may be 
involved in bradyzoite conversion. In addition, the association of the S/M phase 
of the tachyzoite cell cycle with bradyzoite conversion encourages closer look at 
those AP2 factors with cyclical or “cell cycle regulated” mRNA expression.  
Of the 68 T. gondii AP2 proteins, 24 exhibit cyclical mRNA profiles through 
the tachyzoite cell cycle. The temporally-specific expression of this subset of the 
T. gondii AP2s may also be central for their method of mediating parasite 
development. Indeed, in Plasmodium, the 28 ApiAP2s are expressed at distinct 
periods during development, aligning with the temporal appearance of 
developmentally regulated genes (141). This “just-in-time” mechanism may be 
important to ApiAP2s in other Apicomplexans as well. In particular, the cellular 
changes linking the tachyzoite cell cycle and initiation of bradyzoite development 
at the S/M phase require further clarification.  
 Evaluation of transcriptome data revealed that four of AP2 factors which 
are induced under in vitro bradyzoite conditions also demonstrate S phase peak 
expression (156). One of these, AP2IX-4, is also upregulated during chronic 
infection in mice (159). These data demonstrate that transcript levels of AP2IX-4 
are upregulated in both in vitro and in vivo bradyzoite conditions. In addition, 
AP2IX-4 transcript expression is cell cycle-regulated in the tachyzoite stage, and 
AP2IX-4 contains a putative DNA-binding domain. Therefore, we hypothesize 
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that AP2IX-4 is a cell cycle-regulated transcription factor that contributes to 
the biology of bradyzoite cysts. This hypothesis will be dissected using the 
following aims: 
(1) Using molecular genetics and IFA, evaluate the expression of AP2IX-4 
protein in the bradyzoite stage compared to the tachyzoite stage  
(2) Examine the role of AP2IX-4 in tachyzoite replication and in both in 
vitro and in vivo models of bradyzoite induction.  
(3) Evaluate the genes whose expression are under direct or indirect 
control of AP2IX-4.  
(4) Generate reagents for a yeast two-hybrid screen towards the goal of 
identifying AP2IX-4 interacting proteins.  
The long-term goals of this thesis are to illustrate the molecular basis for the 
transcriptional reprogramming that occurs in the tachyzoite-to-bradyzoite 
conversion. Based on previous studies, this transcriptional reprogramming is 
accompanied by a temporal cascade of gene activation or repression and 
changes in acetylation status on promoters of stage-specific genes. The 
evaluation of AP2IX-4 protein expression throughout the tachyzoite cell cycle 
and bradyzoite time course aims to compare this data with existing 
transcriptome data of AP2IX-4 expression. Knockout and transcriptional 
analysis experiments will specify possible functions this factor plays in 
bradyzoite development, with eventual Y2H results indicating the mechanistic 
complexes in which the factor participates towards its role.  
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CHAPTER 2: MATERIALS AND METHODS 
 
I. Tissue culture techniques 
 
A. Parasite strains and sources  
Modified versions of two parental parasite lines were used for this thesis: a 
type I strain, RH, a type II strain Prugniaud (abbreviated “Pru”). All the parasite 
lines used in this thesis are summarized in Table 1. Parasites were modified to 
contain deletions of the non-homologous end joining enzyme ku80 and/or the 
hxgprt gene, resulting in the parasite lines used as parental backgrounds in this 
thesis, RH∆ku80::HXGPRT and Pru∆ku80∆hxgprt. Wild-type RH parasites were 
used to generate the total RNA for construction of the yeast two-hybrid library, 
described in Section VI.A.  
The Pru∆ku80∆hxgprt line in this thesis was originally generated in (160), 
and the RH∆ku80::HXGPRT line is derived from the parasite line originally 
generated in (161). These two studies demonstrated that deletion of ku80 
promotes DNA repair via homologous recombination over non-homologous end 
joining, a manipulation employed in the generation of parasite mutants for allelic 
replacement via homologous recombination (160, 161). Pru∆ku80∆hxgprt 
parasites also contain ectopic integration of three copies of a construct that 
expresses green fluorescent protein (GFP) under the bradyzoite-specific LDH2 
promoter (118). This line was generated at the John Boothroyd Lab at Stanford 
University and is described in (118). Deletion of hxgprt sets up a selection 
system discussed in Section I.H. 
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Table 1. Parasite lines 
 
Line Parental Strain Features and Notes 
RH∆ku80::HXGPRT RH Deletion of ku80 
promotes homologous 
recombination over 
non-homologous end-
joining DNA repair 
Pru∆ku80∆hxgprt Pru Deletion of hxgprt sets 
up drug selection 
system explained in 
Chapter 2 Section 
I.H.; Contains ectopic 
integration of three 
copies of a construct 
that expresses gfp 
under the bradyzoite-
specific LDH2 
promoter 
RH RH Wild-type RH used for 
preparation of total 
RNA for yeast two-
hybrid screen 
AP2IX-4HA RH∆ku80::HXGPRT Parasite line 
containing AP2IX-4 
endogenously tagged 
at its C-terminus with 
three tandem HA tags 
∆ap2IX-4 in Pru Pru∆ku80∆hxgprt Deletion of ap2IX-4 
∆ap2IX-4::AP2IX-4 HA ∆ap2IX-4 in Pru Complementation of 
AP2IX-4 in Pru 
∆ap2IX-4 parasites; 
rescued AP2IX-4 is 
tagged at its C-
terminus with three 
tandem HA tags 
 
B. Host cell and parasite culturing 
T. gondii is capable of invading virtually any nucleated cell in the body. In 
tissue culture work, human foreskin fibroblasts (HFFs) are widely used for 
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several reasons. These cells are easy to culture, reaching confluence in days 
and exhibiting contact inhibition. Invaded parasites form rosettes which, along 
with the large and flat host cells, are easily visualized under the microscope. 
Parasites were cultivated in confluent monolayers of HFFs (ATCC #CRL-4001) 
grown in T25cm2 or T150cm2 flasks (Corning Life Sciences, #353109 or 353110). 
HFFs were cultured in host medium that consisted of Dulbeco Modified Eagle 
Medium (DMEM; Corning #10-017-CV) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS, Gibco #16000). The HFF cultures were grown at 37⁰C 
in a humidified incubator with 5% CO2. All host cell and parasite culturing was 
performed under sterile conditions in a laminar flow hood.  
To expand HFF cultures, HFFs in T150cm2 flasks were trypsinized, diluted 
in HFF medium, and allocated into new T25cm2 or T150cm2 flasks. The host 
medium was aspirated from the HFF monolayer which was then washed with 1x 
phosphate-buffered saline (PBS). Monolayer cells were released for passaging 
using trypsin digestion at 37⁰C for two minutes. Following digestion, the 
monolayers were thoroughly separated from the flask surface by banging the 
sides of the flask using the palm of the hand. The cells were then resuspended in 
new host medium at a dilution of 1:5 or 1:10. This cell resuspension was then 
allocated into T25cm2 flasks with 10 mL of culture per flask or into T150cm2 flasks 
with 50 mL of culture per flask. The new monolayers were then cultured at 37⁰C 
with 5% CO2. 
HFFs lose their ability to reach confluency as they age; they cannot be 
expanded indefinitely. Therefore, the number of expansions or “passage number” 
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of an HFF culture is recorded on the flask with each trypsinization. To maintain 
healthy, confluent HFF cultures for both tachyzoite and bradyzoite growth, HFF 
cultures were discarded after passage 20. Younger passage HFF cultures from 
either existing in-culture lines or thawed lines were then used to generate new 
lines. 
Indirect immunofluorescence (IFA) experiments utilized HFFs cultured in 
12-well plates (Fisher, #07-200-81) with coverslips. The wells of the plate were 
first populated with coverslips by aspirating autoclaved coverslips from a storage 
dish and depositing the coverslips into the well via gentle dislodging motion of the 
aspirator. 2 mL of trypsinized and resuspended HFFs were cultured per well. 
Cloning with the limiting dilution technique employed 96-well plates (Fisher, #07-
200-90), which were prepared by resuspending trypsinized HFFs in 20 mL of 
host medium. From this, 2.7 mL was added to 115 mL of host medium and the 
diluted culture was then allocated into a sterile solution basin (VWR, #21007-
972). Using a multi-channel pipettor, the mixture was aliquoted into the wells of 
the 96-well plate with 200 uL per well.  
Depending on the volume of T. gondii used to infect HFFs in a flask, 
parasites invade, replicate and lyse a monolayer in the span of several days. 
Since T. gondii is an obligate intracellular parasite, an absence of HFF 
monolayer for invasion means parasites linger without host cells. Viability of the 
parasites declines with increasing time outside of host cells, therefore 
propagation of parasite cultures requires fresh host cells before or immediately 
following complete lysis of the original monolayer. To propagate parasite 
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cultures, aliquots of extracellular parasites were passed into T25cm2 flasks with 
fresh HFF monolayers whose host medium had been replaced with parasite 
medium. Parasite medium consists of DMEM supplemented with either 1% (for 
type I, RH background parasites; see Section I.A and Table 1) or 5% (for type II, 
Pru background parasites; see Section 1.A and Table 1) FBS. Parasites were 
then cultured in at 37⁰C in a humidified incubator with 5% CO2.  
 
C. Parasite growth assays 
Parasite doubling assays were performed as previously described (148). 
In brief, 106 freshly lysed tachyzoites were inoculated onto host cell monolayers. 
After 24 hours, the number of tachyzoites present within 50 random vacuoles 
was recorded at 12 hour intervals. For plaque assays, infected monolayers in 12-
well plates were fixed with 4% para-formaldehyde (PFA) and stained with crystal 
violet to visualize and count plaques, which are areas of parasite lysis in the host 
monolayer (149). 
 
D. In vitro bradyzoite induction  
To initiate conversion to bradyzoites in vitro, type II parasites were allowed 
to invade HFF monolayers for four hours under normal culture conditions, then 
the medium was replaced with Roswell Park Memorial Institute (RPMI) medium 
without sodium bicarbonate (Sigma-Aldrich #R6504) adjusted to pH 8.2 with 
NaOH. Cultures were then moved to a 37oC incubator with ambient CO2. 
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E. Harvesting of parasites 
To control for consistent viability between strains, parasites were 
harvested when they were intracellular. Parasites were harvested by scraping the 
infected HFF monolayer with a cell scraper (Fisher, #50-476-477) and passing 
the culture through a 25-gauge syringe needle (Excel International, #26046) to 
extrude the parasites from the host cells. HFF debris was separated from the 
parasites by passing the syringe-lysed mixture through a 3-micron pore filter 
(Fisher # NC9655197). 
 
F. Freezing and thawing of cells 
Parasites were frozen down in parasite freeze mix to create stocks for 
future use. To prepare freeze mix, 6.3 mL of dimethyl sulfoxide (DMSO) was 
added to 13.8 mL of DMEM and sterile-filtered with a 0.2-micron pore filter unit. 5 
mL of 1% or 5% heat-inactivated FBS was added to the mix, which was then 
stored at 4⁰C. For freezing, intracellular parasites were harvested by scraping 
their host monolayer without syringe-lysing, and the cells were pelleted in by 
centrifugation at 1500xg at room temperature for 10 minutes. The pellet was then 
resuspended in a 1:1 ratio of ice cold parasite medium to freeze mix, and the 
cells then transferred into sterile CryoTubes (Cole-Parmer, #368632). The tubes 
were stored at -80⁰C immediately followed by transfer to the liquid nitrogen 
storage. Frozen parasite stocks were thawed by incubating the CryoTubes in a 
37⁰C water bath. Immediately after thawing, the cells were transferred into T25 
flasks containing parasite medium.  
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G. Transfection 
Electroporation, a technique which introduces pores in the plasma 
membrane, remains a successful method-of-choice to introduce DNA into T. 
gondii parasites (162). It has been shown that cell survival is improved when 
electroporated cells are buffered in a medium that closely mimics the osmolarity 
and ionic composition of the cytosol (163). For this reason, T. gondii tachyzoites 
are electroporated in the presence of a potassium phosphate-based buffer called 
Cytomix consisting of 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4 at 
pH 7.6, 25 mM HEPES at pH 7.6, 2 mM EGTA, and 5 mM MgCl2. (164). 
For electroporations, 50ug of DNA was first linearized via digestion 
overnight using a single-cut restriction enzyme. The digested DNA was purified 
with ethanol precipitation, by combining the DNA with a 0.1 volume of 3M sodium 
acetate, pH 5.2 and 2.5 volume of 100% ice cold ethanol followed by 
centrifugation of the mixture at 21,000xg at 4⁰C for 20 minutes. The pellet was 
then washed with 70% ethanol before final centrifugation at 21,000xg at 4⁰C for 5 
minutes. The ethanol was removed in the sterile laminar flow hood where the 
DNA pellet was allowed to dry for one hour.  
Freshly lysed or intracellular parasite vacuoles were harvested for 
electroporation. The infected monolayer within the flask was scraped, passed 
through a 25-gauge syringe needle, and filtered using a sterile 3-micron pore 
filter unit. The purified parasites were quantified using a hemocytometer to 
allocate 2x107 parasites, which were spun down at 1,500xg at room temperature 
for 10 minutes. Parasites were resuspended in 350 uL of sterile-filtered Cytomix 
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and combined with the purified DNA. The sample was then transferred to a 2 mm 
gap cuvette (Fisher #BTX620). Parasites were pulsed with 1.5 kV, 25 Ω and 25 
uF using a BTX ECM 630 electroporator. Following electroporation, parasites 
were allowed to recover in the cuvette at room temperature for 20 minutes. The 
transfected parasites were then allocated at equal volume into three flasks 
containing confluent HFF monolayers whose host medium was replaced with 
parasite medium. 
 
H. Drug selection of transfected parasites  
Purine salvage and folate synthesis underlie the biochemical basis for two 
common methods of selection of transgenic T. gondii. HXGPRT, one of the 
enzymes in the purine salvage pathway, catalyzes the conversion of 
hypoxanthine, xanthine or guanine to intermediates or products of guanine-
monophosphate (GMP) synthesis (165, see Figure 2). Treatment of ∆hxgprt 
parasites with mycophenolic acid (MPA) is efficiently lethal as MPA inhibits IMP 
dehydrogenase and thus production of inosine monophosphate (IMP) and GMP 
(165). On the other hand, ∆hxgprt parasites transfected with a copy of the 
HXGPRT gene and supplemented with xanthine can rescue GMP production 
(166, Figure 2). MPA and xanthine can thus be used to select for ∆hxpgrt 
parasites transfected with plasmids encoding a copy of HXGPRT. MPA is added 
to cultures post-transfection at a final concentration of 25 ug/mL, and xanthine at 
50 ug/mL.  
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Figure 2. HXGPRT drug selection employs the biochemical basis of 
purine salvage in T. gondii. A. A simplified schematic of the purine salvage 
pathway in T. gondii. The adenosine kinase and HXGPRT pathways are two 
pathways of adenosine monophosphate (AMP) and guanosine 
monophosphate (GMP) production. Hypoxanthine, xanthine and guanine are 
all potential substrates of hypoxanthine-xanthine-guanine phosphoribosyl 
transferase (HXGPRT). B. Steps in the pathway that are inhibited in ∆hxpgrt 
parasites with mycophenolic acid (MPA) treatment. MPA inhibits IMP 
dehydrogenase that catalyzes the conversion of IMP to xanthosine 
monophosphate (XMP). With inhibition of both HXGPRT and IMPDH, GMP 
synthesis does not occur and parasites perish. C. ∆hxgprt parasites rescued 
with an ectopic copy of HXGPRT and xanthine supplementation restore GMP 
synthesis. 
48 
Pyrimethamine inhibits dihydrofolate reductase-thymidylate synthase 
(DHFR-TS), the enzyme catalyzing the conversion of tetrahydrofolic acid from 
dihydrofolic acid (68). Inhibition of this biochemical step prevents the production 
of thymine for DNA synthesis. The DHFR*-TS drug selection cassette carried by 
plasmids used for parasite cloning contains a mutation that renders the enzyme 
resistant to pyrimethamine (167). For selection, pyrimethamine is added at a final 
concentration of 1 uM to transfected cultures.  
 
I. Cloning by limiting dilution 
Transfected parasites were passed at least three times in the presence of 
drug before single parasite clones were isolated using the limiting dilution method 
accomplished in 96-well plates containing HFF monolayers. Dilutions were 
prepared that estimated the allocation of one parasite per well. The plates were 
placed in humidified incubators at 37⁰C with 5% CO2 and left undisturbed for 6-7 
days. The wells were then checked for the presence of single plaques 
representing the lysis of a single population of parasites. Wells containing single 
clones were marked and scraped with the tip of a p200 pipette and the cultures 
transferred into the wells of a 24-well plate containing an HFF monolayer.  
 
II. Plasmid construction  
All primers used for construct generation are summarized in Table 2.  
All plasmids generated for this thesis are summarized in Table 3.  
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A. General PCR protocol 
 Components of the PCR reactions were assembled according to protocols 
optimal for either Taq DNA Polymerase (NEB, #M0273S) or Phusion High-
Fidelity DNA Polymerase (NEB, #M0530S). The high-fidelity Phusion polymerase 
was used for molecular cloning applications in which the accuracy of amplicons 
for sub-cloning was crucial, while Taq polymerase was used for diagnostic 
screening of cloning products. All components of the PCR reactions were 
assembled on ice, with the polymerase aliquoted last. Annealing temperatures 
for Taq polymerase reactions were in general determined by subtracting five 
degrees from the lower annealing temperature of the primer pair, while annealing 
temperatures for Phusion polymerase reactions were determined through 
http://tmcalculator.neb.com/#!/. The general PCR protocols and cycling 
conditions for the Taq and Phusion polymerase systems are given below: 
Components Taq polymerase Phusion polymerase 
 5 uL, 10x Standard Taq polymerase 
buffer 
10 , 5x Phusion HF buffer  
 1 uL, 10mM dNPT 1 uL, 10 mM dNTPs 
 1 uL, 10uM sense primer 2.5 uL, 10 uM sense 
primer 
 1 uL, 10 uM antisense primer 2.5 uL, 10 uM antisense 
primer 
 Variable, DNA template  Variable, DNA template 
 To 50 uL: nuclease-free water To 50 uL: nuclease-free 
water 
 0.25 uL, Polymerase 0.5 uL, Polymerase  
Cycling    
Denaturation 95⁰C, 30s 98⁰C, 30s 
 95⁰C, 30s 98⁰C, 30s 
25-30 cycles Tm, 30s Tm, 30s 
 68⁰C, 1 minute/kb 72⁰C, 30s/kb 
Final 
extension 
68⁰C, 5 minutes 72⁰C , 10 minutes 
Hold 4⁰C 4⁰C 
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Table 2. PCR primers 
 
Underlined and bold indicate sequences for molecular sub-cloning purposes. 
Application Primer Amplicon 5’ 3’ Sequence 
 
Endogenous 
tagging 
 
F1 
 
C-terminus 
of AP2IX-4 
 
TACTTCCAATCCAATTTAATGCA
GCACGATCCAACTCGCCCT 
 
Endogenous 
tagging 
 
R1 
 
C-terminus 
of AP2IX-4 
 
TCCTCCACTTCCAATTTTAGCTC
GCAGGACGGGGACGCTG 
 
Deletion of  
AP2IX-4 
 
F2 
 
AP2IX-4 
upstream 
genomic 
 
GGGGACAACTTTGTATAGAAAA
GTTGCTCGCAACAGCCACTCCCC
G 
 
Deletion of  
AP2IX-4 
 
R2 
 
AP2IX-4 
upstream 
genomic 
 
GGGGACTGCTTTTTTGTACAAAC
TTGCCAACAACGCAAGCACGCC
C 
 
Deletion of  
AP2IX-4 
 
F3 
 
AP2IX-4 
downstream 
genomic 
 
GGGGACAGCTTTCTTGTACAAA
GTGGTCAACACGGCGTCCAGCG
TC 
 
Deletion of  
AP2IX-4 
 
R3 
 
AP2IX-4 
downstream 
genomic 
 
GGGGACAACTTTGTATAATAAA
GTTGGCCGATCACGCCACTCCCT
G 
 
Deletion of  
AP2IX-4 
 
F4 
 
DHFR*-TS 
minigene 
 
GGGGACAGCTTTCTTGTACAAA
GTGGCTCAGGAAAGACAGGCTC
CGGA 
 
Deletion of  
AP2IX-4 
 
R4 
 
DHFR*-TS 
minigene 
 
GGGGACAACTTTGTATAATAAAG
TTGCTGACCGCTGATACATGATG
CA 
 
Deletion of 
AP2IX-4 
 
F5 
 
DHFR*-TS 
minigene 
 
TATCTAGAGACCCCCAAGAGGG
GCATC 
 
Deletion of  
AP2IX-4 
 
F6 
 
DHFR*-TS 
minigene 
 
TAGCGGCCGCGGGGACCACTTT
GTACAAGAAAGCTGGGTAGGAT
CGATCCCCCGGTTTG 
 
Complementation  
 
F7 
 
AP2IX-4 
upstream 
 
TTCCAATCCAATTTAGCCACCGC
TACCATGACTGGGGA 
 
Complementation  
 
F8 
 
AP2IX-4 
upstream 
 
CCCCCCGTGTCTACCGACAT 
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Complementation  
 
F9 
 
AP2IX-4 
CDS 
 
ATGTCGGTAGACACGGGGGG 
 
 
Complementation  
 
F10 
 
AP2IX-4 
CDS 
 
TGCGAGATACTTGGGGACGCA 
 
 
Complementation  
 
F11 
 
AP2IX-4 
CDS 
 
TGCGTCCCCAAGTATCTCGCA 
 
 
Complementation  
 
F12 
 
AP2IX-4 
CDS 
 
CCACTTCCAATTTTAGCTCGCAG
GACGGGGACGCT 
 
B. General molecular cloning guidelines  
 In-Fusion® HD Cloning (Clontech, # 638910) was used for the 
construction of the plasmids detailed in this thesis. In-Fusion cloning operates on 
the ligation of a linearized vector to PCR-amplified fragments that contain 
extensions complementary to the vector at its restriction cut site. These 
homologous end sequences are appended onto the fragments through PCR 
amplification with primers that contain both vector- and insert-specific sequences. 
Therefore, the first step of In-Fusion cloning is to generate the linearized vector 
through restriction digest and to amplify the insert fragment.  
To purify the insert fragment and linearized vector, the products were 
resolved on a 0.8% agarose gel, and bands of the correct sizes were excised 
using a metal scalpel. The vector and insert fragment were gel-purified using the 
PureLink Quick Gel Extraction Kit (ThermoFisherScientific, # K210012), then 
combined in an In-Fusion Reaction at a 2:1 insert-to-vector molar ratio, with at 
least 50 ng of insert. The final component of the In-Fusion Reaction is the In-
Fusion HD enzyme, which generates single-stranded 15-nucleotide regions at 
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the ends of the insert and vector. These single-stranded regions then ligate due 
to their complementarity. All components of the In-Fusion Reaction were added 
to an Eppendorf tube on ice, and the completed reaction was incubated at 50⁰C 
for 15 minutes according to the protocol before cooling on ice.  
Recombinant clones were isolated through transformation in DH5α high-
efficiency competent E. coli (NEB, #C2987H). 50 uL of the competent DH5α cells 
were thawed on ice and then combined with 2.5 uL of the In-Fusion reaction. The 
mixture was incubated on ice for 30 minutes, heat-shocked for 45 seconds at 
42⁰C, then placed on ice for two minutes. 500 uL of Super Optimal Broth with 
Catabolite Repression (S.O.C) medium (Invitrogen #15544034) was added to the 
cells before the cells were incubated with shaking at 37⁰C for one hour. The 
transformation reaction was then plated at two separate volumes onto LB plates 
containing antibiotic for selection. Plates were incubated overnight at 37⁰C for 12-
16 hours.  
To screen for molecular clones containing the insert, bacterial colonies 
were picked at random from the LB plate using the tip of a p20 pipette and 
deposited into 5 mL of LB broth containing the selection antibiotic. The bacteria 
was grown at 37C with shaking for up to 16 hours. Up to 2 mL of the culture was 
spun down in 15-mL conical tubes into a pellet for miniprepping, which were 
performed using the FastPlasmid Mini Kit (5 Primer, #2300010). The extracted 
plasmids were screened for the presence of insert using either restriction digest 
and/or diagnostic PCR. Putative positive clones were sent for sequencing at 
ACGT, Inc., and glycerol stocks of confirmed clones were prepared by adding 
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700 uL of culture to 300 uL of glycerol. Maxipreps of plasmids for transfection 
were prepared by inoculating 125 mL of LB broth containing the selection 
antibiotic, shaking the culture for up to 16 hours at 37⁰C, and extracting the 
plasmid using the GenElute™ HP Plasmid Maxiprep Kit (Sigma-Aldrich, 
#NA0310-1KT).  
All primers utilized to generate constructs and the plasmid maps for all 
constructs utilized in this thesis are provided at the end of this chapter (Figures 
3-5).  
Table 3. Plasmids 
 
Plasmid Purpose in this thesis Features and Notes 
 
pLIC-3HA-DHFR 
 
Parent for pLIC-AP2IX-4-
3HA-DHFR 
 
 
pLIC-AP2IX-4-3HA-
DHFRTS 
 
Endogenous tagging of 
AP2IX-4  
 
 
pDONR_P2R-P3-3arm 
 
Deletion of AP2IX-4 
 
Entry vector for Gateway 
cloning; contains 3’ 
homology arm 
 
pDONR_P4P1R-5arm 
 
Deletion of AP2IX-4 
 
Entry vector for Gateway 
cloning; contains 5’ 
homology arm 
 
pDONR221-DHFRTS 
 
Deletion of AP2IX-4 
 
Entry vector for Gateway 
cloning; contains DHFR*-
TS 
 
pDEST_AP2IX-4KO 
 
Deletion of AP2IX-4 
 
Construct transfected 
into PruQ parasites  
 
pLIC-3HA-HXGPRT 
 
Parent of pLIC-AP2IX-4-
3HA-HXGPRT 
 
 
pLIC-AP2IX-4-3HA-
HXGPRT 
 
Complementation in 
∆ap2IX-4 parasites  
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C. Construct for endogenous tagging of AP2IX-4 
RH∆ku80::HXGPRT parasites were engineered to express endogenous 
AP2IX-4 tagged at its C-terminus with three hemagglutinin (3xHA) epitopes. 
Modification of the endogenous AP2IX-4 locus was achieved through allelic 
replacement of parasites lacking the non-homologous end joining repair enzyme 
KU80 to promote homologous recombination. The construct to append the 
endogenous copy of ap2IX-4 with three HA tags was derived from the pLIC-3HA-
DHFRTS vector, which contains three HA tags preceded by a PacI restriction 
cloning site (Figure 3). Ligation of the insert at the PacI site appends the three 
epitope tags at the C-terminus of the insert.  
The final tagging construct, pLIC-ap2IX-4-3HA-DHFRTS, employed a 
1514 bp C-terminal sequence from genomic AP2IX-4 for homologous 
recombination, amplified with primers F1 and R1 shown in Table 2. The fragment 
was ligated to the PacI-linearized vector in an In-Fusion reaction, which was then 
transformed into DH5α competent E. coli. An ampicillin resistance cassette on 
the plasmid allowed positive selection of bacteria clones, which were then 
screened for transformation with vector containing the 1514 bp insert. Plasmids 
containing the 1514 bp were sent for sequencing to confirm correct sequence in 
the recombinant construct.  
 
D. Construct for knocking out ap2IX-4 
 Deletion of AP2IX-4 in Pru∆ku80∆hxgprt (PruQ) parasites was achieved 
using allelic replacement of the endogenous AP2IX-4 locus with a DHFR*-TS 
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drug selection cassette. The “knockout construct” flanks the dhfr*-ts minigene 
with 1.6-1.9kb sequences that are homologous to regions of the ap2IX-4 locus 
up- and downstream of the coding region. To design this multi-fragment 
construct, the MultiSite Gateway Three-Fragment Vector Construction Kit 
(ThermoFisherSci, # 12537100) was utilized by adapting manufacturer protocol. 
One attractive feature of the MultiSite Gateway Three-Fragment cloning 
method is its restriction enzyme-free system that allows recombination of several 
sequences in one reaction. Gateway Cloning is an in vitro modification of events 
occurring during the integration of lambda (λ) bacteriophage DNA into E. coli. 
The λ phage is able to integrate into E. coli DNA at att sites. The phage attP 
targets the bacterial attB site, generating attL and attR sites at the recombination 
loci. In Gateway Cloning, the att sites have been modified such that directional 
recombination can occur. DNA sequences-of-interest, usually generated in PCR 
reactions, contain the attB sites while “donor” vectors contain the attP sites. In 
brief, Gateway cloning is divided into two steps:  
(1) Generation of entry vectors. Entry vectors are generated in a “BP” reaction 
which mixes attB site-flanking PCR products and attP-containing donor 
vectors. At the recombination sites, attL and attR sites are generated: 
attB x attP  attL x attR 
Entry clones are transcriptionally silent. They must be subcloned into a 
destination vector, a reaction that generates the expression clone. 
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(2) Generation of the expression clone. Entry vectors, containing their attL 
sites, are combined with a destination vector to produce the expression 
clone.   
To generate the AP2IX-4 deletion plasmid, two entry vectors were 
constructed that included 5’ and 3’ flanking sequences for homologous 
recombination at the AP2IX-4 genomic locus. Entry vector pDONR_P4P1R-5arm 
contained a 1,660 bp sequence upstream of the AP2IX-4 genomic sequence, 
while entry vector pDONR_P2R-P3-3arm contained the 1,875 bp sequence 
downstream. A third entry vector, pDONR221-DHFRTS, was constructed to 
contain the dhfr*-ts minigene. The three entry vectors were combined in a 
Gateway LR reaction with the destination vector pDEST_R4R3 to create the final 
knockout plasmid pDEST_AP2IX-4KO (Figure 4). All PCR primers used to 
generate these vectors are listed in the Table 1. 
 
E. Construct for complementation of AP2IX-4 in ∆ap2IX-4 parasites 
Complementation of AP2IX-4 in ∆ap2IX-4 parasites was achieved with 
ectopic expression of triple HA-tagged AP2IX-4. The complementation plasmid 
was generated from the pLIC-3HA-HXGPRT plasmid. This plasmid contains a 
PacI site to integrate the sequence-of-interest which would then be fused at its C-
terminus to the 3HA tags engineered into the plasmid.  
The sequence-of-interest cloned into the pLIC-3HA-HXGPRT vector is a 
2,116 bp sequence used for homology recombination, followed by the entire 
coding sequence of ap2IX-4 (minus the stop codon). The 2,116 bp sequence 
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immediately upstream the ap2IX-4 start codon was amplified from PruQ cDNA 
using primers F7 and F8 (see Table 2) and ligated to ap2IX-4 coding sequence. 
Primers F9, F10, F11 and F12 were used to amplify the ap2IX-4 coding 
sequence, with F9 and F10 amplifying the upstream and F11 and F12 amplifying 
the downstream region. The coding sequence amplicons and the 2,116 bp 
homology amplicon were then ligated using In-Fusion Cloning and integrated into 
pLIC-3HA-HXGPRT at the PacI restriction site. The resulting plasmid (Figure 5) 
was electroporated into ∆ap2IX-4 PruQ parasites. Transgenic parasites were 
selected for using mycophenolic acid and xanthine and cloned by limiting dilution. 
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Figure 3. Final construct used to tag endogenous AP2IX-4 in RH∆ku80 
with three tandem HA tags. Features of the plasmid include the three HA 
epitopes preceded by a 1,514 bp homology region used for allelic replacement 
through homologous recombination. The ampicillin resistance cassette allows 
for selection of bacteria clones containing the construct, and the DHFR*-TS 
drug selection cassette allows for pyrimethamine selection of transgenic 
parasites. Schematic generated with SnapGene® software (from GSL 
Biotech; available at snapgene.com). 
59 
 
 
 
 
 
Figure 4. Final construct used to delete AP2IX-4. Flanking the DHFR*TS 
drug selection cassette are sequences upstream (1,660 bp) and downstream 
(1,875 bp) to genomic AP2IX-4 which are used for homologous 
recombination. Schematic generated with SnapGene® software (from GSL 
Biotech; available at snapgene.com) 
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Figure 5. Construct used to complement AP2IX-4 in ∆ap2IX-4 parasites. 
Upstream of the AP2IX-4 is a 2,116 bp genomic sequence used for 
homologous recombination at the AP2IX-4 locus. Re-constitution of AP2IX-4 
in ∆ap2IX-4 parasites appends three HA epitopes at its C-terminus through 
the tandem HA repeats in the construct. Schematic generated with 
SnapGene® software (from GSL Biotech; available at snapgene.com). 
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III. Biochemical techniques 
 
A. Western blot  
Parasites were harvested when intracellular by scraping infected host 
monolayer and extruding the intracellular parasites with passage through a 25-
gauge syringe. Host debris was filtered out by passing this mixture through a 3 
micron pore membrane. To prepare pellet samples with equal parasite material, 
purified parasites were quantified using the hemocytometer and an equal number 
of parasites for each parasite strain was allocated into 15-mL conical tubes 
before centrifugation at 1,500xg for 10 minutes at room temperature. The 
parasite medium was aspirated and the parasite pellet was resuspended in 
parasite lysate buffer (150 mM NaCl, 50 mM Tris-Cl pH 7.5, 0.1% NP40) mixed 
with mammalian protease inhibitor cocktail (Sigma, # P8340-5ML) to prevent 
enzymatic degradation of proteins. The mammalian protease inhibitor cocktail 
was added at 10 uL per 1 mL of parasite lysis buffer. The parasite sample was 
then incubated at 4⁰C for 30 minutes with gentle shaking. Afterwards, the lysate 
was sonicated 15 seconds three times, with 30 seconds on ice between each 
sonication. Insoluble debris was separated from soluble cellular components by 
centrifugation at 21,000xg at 4⁰C or 20 minutes and discarding the pellet.  
Denaturation and reduction of disulfide bonds in the soluble proteins was 
achieved by preparing β-mercaptoethanol in 4x NuPAGE LDS Sample Buffer 
(Fisher # NP0007), adding this buffer at a ratio of 1:4 to the lysate, and 
incubating the sample on a 95⁰C for ten minutes. Samples were then loaded into 
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the wells of a pre-cast 4-12% Bis-Tris gel (Fisher, #NP0322BOX) and 
electrophoresed in MOPS buffer for 55 minutes at 200 V, 120 mA and 25 W. 
Nitrocellulose membrane (GE Healthcare Life Sciences, # 10600004) was used 
for transfer of protein performed at 35V for 1.5 hours, after which the quality of 
transfer was assessed using Ponceau staining. Membranes were blocked in 4% 
milk/TBST for 30 minutes.  
Rat anti-HA primary antibody (Roche, #11867423001) was applied at 
1:5000 dilution to the membrane overnight at 4⁰C with gentle shaking followed by 
anti-rat antibody conjugated to horseradish peroxidase (HRP) (GE Healthcare 
Life Sciences, #NA935) at 1:2000 dilution. Rabbit anti-β-tubulin antibody (kindly 
supplied by Dr. David Sibley, Washington University) was applied at 1:2,000 
dilution followed by HRP-conjugated donkey anti-rabbit antibody (GE Healthcare) 
at 1:2,000. Proteins were visualized using chemiluminescence catalyzed by HRP 
on SuperSignal™ West Femto Maximum Sensitivity Substrate 
(ThermoFisherScientific, #34094) and detecting the signals using the FluorChem 
E Imager and AlphaView® software (Protein Simple).  
 
B. Indirect immunofluorescence assay 
HFF monolayers grown on coverslips in 12-well plates were inoculated 
with freshly lysed parasites. Infected monolayers were fixed in 4% para-
formaldehyde (PFA) for 10 min, quenched in 0.1 M glycine for 5 min, and then 
permeabilized with 0.3% Triton X-100 for 20 min with blocking in 3% BSA/1xPBS 
for 30 min.  
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IFAs of tachyzoite cultures:  Rabbit polyclonal anti-HA primary antibody 
(Invitrogen) was applied at 1:2,000 dilution overnight at 4oC, followed by goat 
anti-rabbit Alexa Fluor 488 secondary antibody (Thermo Fisher) at 1:4,000 
dilution. Detection of IMC3 was achieved using rat monoclonal anti-IMC3 
antibody (kindly supplied by Dr. Marc-Jan Gubbels, Boston College) at 1:2,000 
dilution overnight at 4oC, followed by goat anti-rat Alexa Fluor 594 antibody 
(Thermo Fisher) at 1:4,000 dilution. 4’,6-diamidino-2-phenylindole (DAPI, Vector 
Labs) was applied for 5 min as a co-stain to visualize nuclei.  
IFAs of bradyzoite cultures:  Rat monoclonal anti-HA primary antibody 
(Roche # 11867423001) was applied at 1:1,000 dilution for 1 hour at room 
temperature, followed by goat anti-rat AlexaFluor 594 secondary antibody 
(Thermo Fisher #11007) at 1:1,000 dilution. For the visualization of bradyzoite 
cyst walls, rhodamine- or FITC-conjugated Dolichos biflorus lectin (Vector 
Laboratories # RL-1032 or # FL-1031) was applied at 1:1,000 dilution for 30 
minutes at room temperature. In IFAs co-stained for IMC3 or SAG1, rabbit 
polyclonal anti-HA primary antibody (Invitrogen #715500) was applied at 1:2,000 
dilution, followed by goat anti-rabbit Alexa Fluor 568 secondary antibody (Thermo 
Fisher # A-11011) at 1:4,000 dilution. Detection of IMC3 was achieved using rat 
monoclonal anti-IMC3 antibody (kindly supplied by Dr. Marc-Jan Gubbels, 
Boston College) at 1:2,000 dilution overnight at 4oC, followed by goat anti-rat 
Alexa Fluor 647 antibody (Thermo Fisher # A-21247) at 1:4000 dilution. 
Detection of SAG1 was achieved using mouse monoclonal anti-SAG1 antibody 
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(Abcam # ab156836) followed by goat anti-mouse AlexaFluor 568 secondary 
antibody (Thermo Fisher # A-11004). 
 
IV. Gene expression analysis 
 
A. Purification of total RNA 
At least 500 ng of total RNA was used to synthesize target sequences for 
microarray hybridization. Tachyzoite total RNA was purified from intracellular 
PruQ or ∆ap2IX-4 parasites maintained at pH 7.0 (32-36 hours post-infection) or 
PruQ, ∆ap2IX-4 or ∆ap2IX-4::AP2IX-4HA  parasites maintained at pH 8.2 (48 
hours) using the RNeasy Mini kit (Qiagen) according to manufacturer’s 
instructions. Tachyzoite cultures were harvested by first scraping the monolayer 
and syringe-passing the culture through a 27-gauge needle. Host debris was 
filtered out by passing the syringe-lysed culture through a filter membrane with 3 
micron pores. Alkaline-induced cultures were harvested by first scraping the 
monolayer and syringe-passing the culture through a 27-gauge needle, and host 
debris was separated by filtering the culture twice through a filter with 5 micron 
pores. The purified parasites were then centrifuged at 4⁰C 1,500xg for fifteen 
minutes. The sample was then washed three times total with PBS, with 
centrifugation at 10,000 rpm at 4⁰C for 5 minutes between each wash. After the 
final wash and centrifugation, the supernatant was removed and the pellet was 
immediately used for total RNA extraction.  
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The RNeasy Mini kit (Qiagen, # 74104) was used to extract total RNA per 
manufacturer’s instructions. A Nanodrop was used to quantify the total RNA. To 
check the quality of the total RNA and amount of contaminating host material, an 
aliquot of the sample was run on a 0.8% agarose gel. The Nanodrop 260/280 
reading was used to assess organic contaminants, and a final analysis of quality 
was performed by the Agilent 2100 Bioanalyzer instrument.  
 
B. ToxoGeneChip description  
The availability of a sequenced, annotated genome from the T. gondii 
strain ME49 along with the identification of single nucleotide polymorphisms 
(SNPs) from genome mapping and expression sequence tag (EST) projects 
made it possible to populate the T. gondii GeneChip with probe sets for a variety 
of applications. The design of the T. gondii GeneChip considers practical 
applications such as global parasite transcriptome comparisons, gene discovery, 
comparisons of single nucleotide polymorphisms between strains, and pilot 
projects such as chromatin immunoprecipitation and antisense expression (168). 
Each gene is represented by at least eleven 3’ biased perfect-match (PM) 
probes, which are 25-mer oligonucleotides spotted using photolithography. Of the 
~8,000 annotated ME49 genes, 3’ biased PM probes were designed for 7,793 
(168). Annotated genes include nuclear genes which comprise the largest portion 
of the array (39%) and apicoplast and mitochondrial genes (168). Other probe 
sets include those ESTs without predicted gene models and T. gondii markers for 
highly polymorphic genes such as SAG1/2/3/4, SRS1/2/9/ ROP1/16, AMA1, 
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MIC2, GRA3/6/7 and BSR4 (168). The GeneChip also includes probesets for 
human and mouse genes, notably immune response cytokines and receptors 
(168).  
 
C. Target sequence synthesis, hybridization, and statistical analysis 
A total of 500 ng RNA was used in the Affymetrix One-Cycle kit 
(ThermoFisherSci, # A10752030) to produce cRNA. The fragmented cRNA was 
hybridized to the ToxoGeneChip using standard hybridization protocols. Two 
hybridizations were done for each sample. Hybridization data was processed 
with the Robust Multi-array Average (RMA) approach which subtracted 
background, normalized the intensity signals between gene chips, log2-
transformed the probe level intensities and summarized the intensity values 
within each probe set using per chip and per gene median polishing. The 
processed probe values were then analyzed using the GeneSpring 7.2 (version 
12.6.1) software package (Agilent Technologies, Santa Clara CA). Fold changes 
that were significant (p<0.05) between probe sets were determined using a 
moderated t-test followed by Benjamini-Hochberg multiple-testing correction. 
Transcriptome data from previous publications was used to denote whether 
genes in our datasets were associated with expression in the bradyzoite stage 
(103,159). 
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V. Modeling of parasite infection in mice 
 
A. Acquisition, housing and general care of mice 
Four week old female Balb/c mice were purchased from Harlan. After 
arrival, mice were grouped four per cage, with as close to the same total weight 
per cage as possible, and allowed at least one week to adjust to their 
environment. Mice were fed dry chow pellets which they were able to access 
through a wire overlay. Water was provided through a self-use spigot.  
 
B. Preparation of parasites for injection of mice 
In the infection modeling studies presented in this thesis, each group of 
eight mice was injected with either PruQ, ∆ap2IX-4, or ∆ap2IX-4::AP2IX-4HA 
parasites, with each cage receiving either 107, 106 or 105 parasites. Parasite 
dosages were prepared through serial dilutions. On the day of injections, 
intracellular tachyzoites were harvested by scraping the infected HFF monolayer, 
passing the culture through 25g syringe needle, and filtering out HFF debris 
using a sterile 3 micron filter. Purified parasites were quantified and inspected for 
degree of HFF contamination using a hemocytometer. To prepare serial dilutions, 
the quantity of parasites ten-fold the highest inoculum dosage was aliquoted, 
centrifuged at 1500g for 10 minutes at room temperature, and resuspended in 
1xPBS. This “parasite stock” was used for ten-fold serial dilutions in 1xPBS to a 
final volume of 100 uL. To assess parasite viability across parasite strains, 
plaque assays were performed by inoculating each sample onto confluent HFF 
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monolayers in a 12-well plate with 500, 1000, 2000, and 5000 parasites. These 
plaque assay plates were left undisturbed in a 37⁰C incubator with 5% CO2 for 
six days. Plaque numbers for each strain were quantified to ensure approximate 
viability percentage.  
 
C. Injection and monitoring of mice 
Mice were weighed before injection to obtain the weight at day 0 of the 
experiment. Mice were injected intraperitoneally with 28-gauge needles and 
monitored for weight, scruffiness of appearance and survival. For the acute 
infection study, mortality was recorded daily for up to 14 days and significant 
differences in mice survival were calculated using the log-rank test. For the 
chronic infection study, survivors of the acute infection study were sacrificed at 
day 35 using CO2 asphyxiation followed by cervical dislocation. To confirm 
infection, cardiac bleeds were performed on the mice immediately following 
euthanasia. Cardiac bleeds were deposited into Eppendorf tubes and kept on 
ice. The brains of the dead mice were then extracted and homogenized in 1.3 mL 
PBS, by first grinding with a mortar and pestle followed by pipetting repeatedly 
into finer particulates.  Brains were deposited into Eppendorf tubes and kept on 
ice.  
 
D. Preparation of IFA samples for in vivo cyst burden quantification 
To prepare immunofluorescence assay samples from brain homogenates, 
250 uL of brain homogenate was obtained from the 1.3 mL preparation and spun 
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down at 3000xg for 5 minutes. All subsequent steps, from fixation to final wash, 
were performed by resuspending the pellet with the indicated reagent and time, 
with centrifugation at 3000xg for 5 minutes at room temperature and removal of 
the supernatant between each step. The pellet was fixed under the sterile fume 
hood for 20 minutes with 150 uL 3% methanol-free formaldehyde (prepared from 
16% stock, Electron Microscopy Sciences # 50980487) and quenched with 
150uL of 0.1 M glycine in 1xPBS for 5 minutes. Blocking was performed with 3% 
BSA in PBS in 0.2% Triton X-100 for one hour at room temperature.  
To stain the cyst walls of any bradyzoites, rhodamine-conjugated Dolichos 
bifluorus lectin (source) was applied at 1:250 for one hour at room temperature or 
overnight at 4⁰C. The sample was washed three times with PBS. After the final 
wash, 5 uL of the pellet was deposited onto a glass microscope slide and 
covered with a circular coverslip. Three samples of 5uL each were prepared per 
mouse brain homogenate. The slides were allowed to dry overnight on the 
benchtop before the coverslips were sealed on the rims with nail polish.  
 
E. Quantification of mouse brain cysts  
For each mouse brain, all three IFA samples were scored for the number 
of cysts using the Nikon Eclipse 80i 37 fluorescent microscope. Structures within 
the brain homogenates that were lectin-positive and spherical or ovoid with 
distinct smooth outer “lectin rims” were counted as cysts. Total cyst burden 
approximates per brain were calculated from individual slide counts as previously 
described in (169). 
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VI. Yeast two-hybrid library construction  
 
A. General schematic 
The yeast two-hybrid (Y2H) assay is an approach that identifies interaction 
between two proteins. It utilizes the reconstitution of a yeast transcription factor 
upon interaction of two proteins – the “bait” and the “prey.” The bait protein is 
fused to the DNA-binding domain of the yeast transcription factor, and the prey is 
fused to the activation domain. Interaction of bait and prey reconstitutes the 
transcription factor, allowing recruitment of transcriptional machinery for the 
expression of a reporter gene that allows growth of yeast colonies on selective 
media.  The Y2H system described in this thesis employs activation of yeast 
transcription factor LexA following interaction of LexA DNA-binding domain and 
Gal4 activation domain (Figure 6). The reporter gene is His3 (imidazoleglycerol-
phosphate dehydratase), which allows yeast growth on histidine-lacking medium 
(170).   
Full-length AP2IX-4 protein was prepared as bait by fusing AP2IX-4 to the 
LexA DNA-binding domain. The prey library was developed from cDNA that was 
generated from RH total RNA (see Section B below). Synthesis of cDNA was 
accomplished using random primers (Petra Tafelmeyer of Hybrigenics, personal 
communication, March 8, 2017). Adapters were then appended to the cDNA, and 
adapter-ligated cDNA fragments were inserted at the Sfil restriction site 
downstream of the Gal4 activation domain in the pP6 library vector. The average 
sizes of the inserts were 1,500 nucleotides (Petra Tafelmeyer of Hybrigenics, 
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personal communication, March 8, 2017). Tests for bait auto-activation and 
toxicity, construction of the prey library via fusion of prey cDNAs to the Gal4 
activation domain, and screening was performed by Hybrigenics Services 
(https://www.hybrigenics-services.com).  
 
Figure 6. Schematic of yeast two-hybrid concept. Top panel (A). In the 
absence of a bait-prey interaction, the Gal4 activation domain remains 
separate from the LexA DNA-binding domain and no recruitment of 
transcription machinery occurs. Bottom panel (B). Reconstitution of the 
transcription factor by bait-prey interaction results in recruitment of 
transcription machinery allowing His3 expression. 
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To test for auto-activation, yeast cells transformed with bait plasmid were 
spread on plates lacking tryptophan (to select for the bait plasmid) and lacking 
histidine. The plates also contained 3-aminotriazol (3-AT) at a concentration of 5 
mM. 3-AT is a competitive inhibitor of the product of His3 gene, a protein called 
imidazole glycerol phosphate dehydratase which allows yeast growth on 
histidine-deficient plates (171). To overcome 3-AT inhibition and to grow on the 
selective medium, yeast cells must express sufficient levels of His3 (171). In turn, 
the expression levels of His3 depend on the strength of the interaction between 
bait and prey, with stronger interactions allowing for increased promoter 
activation resulting in increased His3 (171). Thus, higher levels of 3-AT reduce 
auto-activation while lower levels promote identification of low-affinity interactions 
(171). Yeast cells transformed with the AP2IX-4 bait plasmid did not grow on 
plates with 5 mM 3-AT, suggesting that auto-activation was insignificant at this 
concentration of 3-AT.  
Next, an optimal concentration of 3-AT for the screen was determined; 
lower concentrations of 3-AT are more amenable to yeast growth and potential 
false-positives, while higher concentrations are limiting to yeast growth and may 
potentially masking bait and prey interactions. Yeast containing bait plasmid and 
yeast containing prey plasmid were mated, and the mating reactions were spread 
on plates lacking three amino acids (“DO-3 medium” for Drop Out with 3 Amino 
Acids): tryptophan (to select for bait plasmid), leucine (to select for prey plasmid), 
and histidine (to select for interaction). The plates contained either 0.5 mM, 1 
mM, 2 mM, 5 mM or no 3-AT. In this AP2IX-4 3-AT optimization test, 27 clones 
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grew on the plates lacking 3AT, while only 4 clones grew on plates with 0.5 mM. 
Thus, 0.5 mM 3-AT was selected as the optimal 3-AT concentration.  
Bait toxicity was tested by plating one set of mating reactions on full 
medium, containing all amino acids, and another set on medium with all amino 
acids except tryptophan (to select for the bait plasmid). If the bait is not toxic, 
approximately the same number of colonies should grow on both plates. If the 
bait is toxic, fewer colonies will grow on the tryptophan-lacking plate. The AP2IX-
4 bait did not exhibit toxicity. This was consistent with the high number of 
colonies tested in the full-screen, which was more than 50 million (Petra 
Tafelmeyer of Hybrigenics, personal communication, February 10, 2017). 
A total of 54 million colonies in the AP2IX-4 yeast two-hybrid screen were 
tested, representing 5-fold coverage of the library, and a total of 343 clones grew 
successfully on DO-3 medium and were sequenced (Valerie Hindie of 
Hybrigenics, personal communication, October 13, 2016). Out of these 343, 
there were a total of 58 independent hits, and these were ranked by the 
“predicted biological scores (PBS).” The PBS score considers the frequency of 
interactions observed with each prey fragment, the distribution of reading frames 
and stop codons in the prey sequence, and any interactions confirmed by other 
screens (172). Numerically, it ranges from 0 to 1, and is an indication of the 
probability of a non-specific interaction. The range of PBS scores is separated by 
letters indicating each score range: A < 1e-10 < B < 1e-5 < C < 1e-2.5 < D < 1 
(172). PBS D hits represent those whose interaction was detected by one prey 
fragment, suggesting either a true interaction from a protein expressed from a 
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low-expression mRNA in the prey library or a false-positive interaction (172). 
PBS E and F categories were added by Hybrigenics (173); PBS E hits represent 
those containing protein domains that have been mapped to with numerous 
interactions with proteins in a human protein database, while PBS F hits 
represent artifacts of the Y2H assay, such as proteins that bound to LexA, Gal4, 
or DNA sequences upstream of the reporter gene (173).  
 
B. Preparation of total RNA 
1 mg of total RNA for the generation of prey cDNA in the Y2H screen was 
prepared from wild-type RH. RH parasites were seeded onto confluent HFF 
monolayers in T150cm2 flasks and grown to the intracellular, 48 parasite-per-
vacuole stage. Parasites were harvested by scraping the infected HFF 
monolayer and passing the culture through a 25-gauge syringe needle. HFF 
debris was separated from the parasites by passing the syringe-lysed mixture 
through a 3-micron pore filter. Parasites were pelleted by centrifugation at 
3000xg, 4⁰C for 10 minutes. Total RNA isolation was performed using TRIzol 
Reagent (Thermo Fisher #15596026) according to manufacturer’s protocol 
(https://tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf). DNase 
treatment was performed using the DNA-free kit (Thermo Fisher #AM1906) per 
manufacturer’s protocol 
(https://tools.thermofisher.com/content/sfs/manuals/cms_055739.pdf).  
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CHAPTER 3: RESULTS 
A previous study employed microarray analysis to measure the transcript 
expression of T. gondii genes during 12-hour time courses in the tachyzoite 
stage (109). Data from this study revealed that AP2IX-4 (TGME49_288950) 
exhibits cell cycle regulation, with transcript abundance peaking at the boundary 
between the S and M phase. AP2IX-4 is predicted to be a 2,856 bp intron-less 
gene located on chromosome IX (Toxodb.org). The protein mass of AP2IX-4 is 
predicted to be 104 kDa, and the protein sequence is composed of 951 amino 
acids that harbor a single predicted AP2 domain. No other protein domains were 
detected with SMART or Interpro algorithms, and there is no evidence for post-
translational modifications on AP2IX-4. 
 
I.       Alignment and phylogenetic analysis of the predicted AP2 DNA-
binding domain of AP2IX-4 
We performed phylogenetic analyses of the AP2IX-4 protein sequence in 
collaboration with Dr. Chunlin Yang (Gustavo Arrizabalaga Lab, IUSM). BLAST 
searches performed on a 60-amino acid globular region C-terminal to the AT-
hook DNA-binding motif in Plasmodium revealed that this globular region was 
conserved in other Apicomplexa as well (139). Secondary structure prediction 
performed on this globular region found that it includes a core of three 
consecutive β strands followed by an α helix, consistent with the secondary 
structure of AP2 DNA-binding domains found in plants (139). 68 AP2 domain-
containing proteins are predicted in the T. gondii genome, with some proteins 
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containing multiple AP2 domains. To explore the relationships between the 103 
total AP2 domains across T. gondii AP2 proteins, the amino acid sequences for 
the predicted AP2 domains were aligned using Gblock program, which aligns 
multiple sequences by conserved features that are organized into “blocks” 
(http://molevol.cmima.csic.es/castresana/Gblocks_server.html; 174). The results 
of the alignment are shown in Figure 7.   
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Figure 7. Amino acid sequence alignment of AP2 domain of AP2IX-4. The 
predicted AP2 domain of AP2IX-4 was aligned with the other 102 AP2 domains 
across the T. gondii genome. Conserved residues are highlighted in black. 
Blue bars at the bottom of the alignment indicate the three alignment blocks. 
AP2IX-4 (TGME49_288950) is highlighted at the top of the list. 
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Compared to the 102 total AP2 domains across the other T. gondii AP2 
proteins, the predicted AP2 domain of AP2IX-4 was revealed to contain 
conserved glycine, valine and tryptophan residues in the first alignment block and 
a conserved phenylalanine residue in the second block. The third alignment 
block is missing all conserved residues except for an arginine residue. JPRED 4 
algorithms (http://www.compbio.dundee.ac.uk/jpred4/index.html; 175) were used 
to identify any secondary structures in the amino acid sequence of the AP2 
domain of AP2IX-4. AP2IX-4 was determined to include three β strands followed 
by a C-terminal α helix, congruent with the secondary structures of the AP2 
domains found in Plasmodium (139, Figure 8).  
 
The GBlock alignment of the 103 T. gondii AP2 domains was inputted into 
the PhyML 3.0 program (http://www.atgc-montpellier.fr/phyml/; 176) to construct 
a phylogenetic tree using the likelihood-based statistical method (Figure 9). The 
AP2 domain of AP2IX-4 (TGME49_288950) clustered with the AP2 domain of 
AP2X-10 (TGME49_215340), the most C-terminal AP2 domain (483 aa-538 aa) 
of AP2IX-8 (TGME49_306000), and the AP2 domain of AP2IV-2 
(TGME49_320680). AP2X-10 (TGME49_215340) transcripts are upregulated 
  
FKDGVYFDHQKGCWKATVQRRNQVITKHFTEKRTAHTMSVKHPEETRA
TLYYDW 
----EEE-----EEEEEHH---HEEEEEEE-----HHHHHHHHHHHHHHHE--- 
 
Figure 8. Predicted secondary structures in the AP2IX-4 AP2 domain. 
JPRED algorithms were used to predict the secondary structures in the amino 
acid sequence of AP2IX-4 following multiple alignment of the amino sequences 
of the 103 AP2 domains predicted across the 68 AP2 proteins in the T. gondii 
genome. The program assigns each amino acid as belonging to a β sheet 
(“E”), an α helix (“H”) or neither β sheet or α helix (“-“).  
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during in vitro and in vivo bradyzoite induction (103, 159), and AP2IV-2 
(TGME49_320680) expression is elevated during chronic infection in mice (159). 
Thus, the amino acid alignment and phylogeny tree revealed conserved features 
and secondary structures of the AP2 domain of AP2IX-4.  
 
Figure 9. Phylogenetic relationship of T. gondii AP2 domains. A phylogeny 
tree was constructed with PhyML 3.0 using the likelihood-based method and 
visualized using the MEGA 7.0.20 software. Branch numbers represent the 
percentage the branch point occurred out of all assembled trees. The 
accession numbers for the T. gondii reference strain ME49 are given. AP2IX-4 
(TGME49_288950) is boxed in red.  
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II. The predicted and confirmed protein size of AP2IX-4  
Our first aim was to validate the predicted protein size and examine the 
protein expression pattern of AP2IX-4. Towards this goal, a previous postdoctoral 
fellow in the Sullivan Lab, Dr. Ting-Kai Liu, tagged endogenous AP2IX-4 with 
three tandem HA epitopes on its C-terminus in RH∆ku80::HXGPRT parasites. 
The loss of the non-homologous end-joining repair enzyme KU80 in these 
parasites facilitates homologous recombination, allowing more efficient allelic 
replacement of the endogenous ap2IX-4 locus (161). Construct pLIC-AP2IX-4-
3HA-DHFRTS was engineered to contain the last 1,514 bp of the AP2IX-4 
genomic sequence followed by the three HA tags, allowing integration of the 
epitope sequences at the AP2IX-4 genomic region (Figure 10A). The construct 
contained a DHFR*-TS drug selection cassette which confers resistance to 
pyrimethamine and was transfected into RH∆ku80::HXGPRT parasites, and 
transgenic clones were selected for with pyrimethamine and isolated through 
limiting dilution cloning. IFA was used to screen for parasites containing nuclear 
HA signal. One parasite clone that demonstrated nuclear HA signal was named 
AP2IX-4HA and subjected to further analysis by Western blot. Probing with anti-
HA antibody in the Western blog analysis revealed a single band at 112 kDa, 
which matched the predicted 3xHA-tagged protein size (Figure 10B). Anti-β-
tubulin antibody was used as a gel loading control. The generation of the AP2IX-
4HA parasite line confirmed the Toxodb.org prediction for the protein size of 
AP2IX-4 and allowed further examination of protein expression pattern through 
the tachyzoite cell cycle by IFA.  
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Figure 10: Generation of parasites expressing HA-tagged AP2IX-4. Top 
panel (A). Schematic showing the strategy used to generate parasites 
expressing AP2IX-4 tagged at the C-terminus with three HA epitopes 
(AP2IX-4HA) in RH∆ku80::HXGPRT parasites. The AP2IX-4 genomic locus 
is aligned with the pLIC-3xHA construct used for endogenous tagging via 
single homologous recombination. The construct contains a 1,514 bp 
homology region and a dhfr*-ts drug selection cassette. Bottom panel (B). 
Western blot of parental RH∆ku80::HXGPRT and AP2IX-4HA parasites 
probed with anti-HA antibody. Anti-β-tubulin was used to verify presence of 
parasite protein. kD = kilodaltons. 
 
  
III. AP2IX-4 is expressed in the parasite nucleus during the S-M 
phase of the tachyzoite cell cycle 
AP2IX-4HA parasites were employed to study the protein expression of 
AP2IX-4 through the parasite cell cycle. IFAs were performed to detect 
subcellular localization throughout the tachyzoite cell cycle, using co-staining with 
Inner Membrane Complex-3 (IMC3) antibody to help delineate cell cycle stages. 
IMC3 is part of a group of structural, filament proteins called alveolins which are 
located in the subpellicular network underneath the parasite plasma membrane 
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(177). The IMC proteins lend the parasite structural stability. IMC3 is enriched in 
budding daughter cells during late S phase through cytokinesis, so it is a useful 
marker for tracing parasites undergoing daughter cell formation (178).  
In our IFA results, AP2IX-4HA protein localized to the parasite nuclei 
(Figure 11, merged panels). Co-staining with IMC3 identified parasites in 
various cell cycle phases in a population: G1 or S phase parasites exhibited 
fainter IMC3 enrichment at the parasite membrane and absence of budding 
daughter cells, while late S/M parasites exhibited the beginning of daughter cell 
formation, and parasites undergoing mitosis or cytokinesis exhibited more 
complete daughter cell formation (Figure 11, IMC3 panel). Using IMC3 co-
staining, we found that AP2IX-4 HA was undetectable in the G1 phase, appeared 
during the S-M stages, then decreased in expression during cytokinesis (Figure 
11). Therefore, the protein expression of this factor is consistent with its reported 
mRNA profile. In addition, we noted that in parasite vacuoles positive for the 
factor, expression was homogenous amongst all tachyzoites within the vacuole. 
 
IV. AP2IX-4 is dispensable for in vitro tachyzoite replication  
Dr. Ting-Kai Liu generated a gene knockout of AP2IX-4 in the Prugniaud 
(Pru) parasite background by replacing the endogenous AP2IX-4 gene coding 
region using double homologous recombination with the DHFR*-TS selectable 
marker. The allelic replacement vector shown in Figure 12A was transfected into 
the Pru parasite strain lacking KU80 (henceforth abbreviated PruQ).  
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Figure 11: AP2IX-4 is localized to the parasite nucleus and expressed 
predominantly in the S and M phases. IFAs were performed on AP2IX-4HA 
tachyzoites using anti-HA (green). To monitor cell cycle phases, parasites 
were co-stained with anti-IMC3 (red) and DAPI (blue). G1, gap phase; S, 
synthesis phase; M, mitotic phase; C, cytokinesis. Scale bar = 3 microns. 
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Figure 12: Generation of PruQΔap2IX-4 parasites. Top panel (A). 
Schematic illustrating the generation of the AP2IX-4 knockout by allelic 
replacement with a dhfr*-ts minigene.  The AP2IX-4 genomic locus is aligned 
with the construct used for knocking out the ap2IX-4 locus via double 
homologous recombination. The construct contains an upstream 1,660 bp 
homology region, a dhfr*-ts drug selection cassette, and downstream 1,875 bp 
homology region. Bottom panel (B). Genomic PCRs were performed with the 
indicated primers (A-G) to verify replacement of the AP2IX-4 genomic locus 
with the dhfr*-ts minigene. RT-PCR with primers B and E confirmed the 
absence of AP2IX-4 transcripts in PruQΔap2IX-4 parasites. Primers for 
GAPDH were used as a positive control for the RNA preparation. 
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Figure 13: AP2IX-4 is dispensable for tachyzoite replication and viability. 
Top panel (A). Representative doubling assay showing the number of 
parasites/vacuole at 24- and 36-hour time-points post-infection for parental 
PruQ versus PruQΔap2IX-4 parasites. Three independent assays were 
performed with similar results. Bottom panel (B). Plaque assays were 
performed to compare in vitro viability of PruQ versus PruQΔap2IX-4 parasites. 
Three independent assays were performed with similar results. Error bars 
represent standard error of the mean.  
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The generation of the parasite lines containing a deletion of AP2IX-4 
allowed us to investigate the role of AP2IX-4 in T. gondii. Following the isolation 
of transgenic parasite clones via limiting dilution, genomic PCRs were performed 
to screen for ap2IX-4 knockout parasites (Figure 12B, primer set B-E). Primer 
sets were also designed to confirm integration of the DHFR*-TS selection 
cassette at the AP2IX-4 genomic locus (Figure 12B, primer sets A-G and F-D). 
Figure 12B shows the results confirming successful allelic replacement of the 
AP2IX-4 gene in the PruQ background (named Δap2IX-4). RT-PCR was 
performed on mRNA harvested from Δap2IX-4 parasites to verify loss of 
transcript (Figure 12B).  
Parasite replication rates were determined using a doubling assay (Figure 
13A) and viability was examined using a plaque assay (Figure 13B). Neither 
assay revealed a significant difference in the in vitro growth between parental 
and Δap2IX-4 parasites in the PruQ strain (Figures 13A-B). These results 
suggest that, despite its appearance during the S-M stages of the cell cycle, 
AP2IX-4 is not required for tachyzoite replication. 
 
V. AP2IX-4 is expressed throughout bradyzoite development  
Previous evaluation of the transcript expression of cell cycle-regulated 
AP2 proteins during in vitro bradyzoite induction conditions revealed a near 
three-fold elevation of AP2IX-4 transcripts in the type II strain ME49 (142). 
AP2IX-4 transcript was elevated as well during chronic infection of mice (146). To 
examine the function of AP2IX-4 in bradyzoites, we complemented the 
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PruQΔap2IX-4 parasites with a cDNA-derived version of AP2IX-4 tagged with HA 
at its C-terminus to be expressed under the native AP2IX-4 promoter (Figure 
14A). Genomic PCRs using primer sets spanning AP2IX-4 and its flanking 
genomic loci confirmed integration of the complementation construct at the 
disrupted AP2IX-4 locus (Figure 14B).  
 
To validate the predicted size of AP2IX-4, Western blot analysis was 
performed on this transgenic line. As shown in Figure 14C, Western blot analysis 
confirmed the expected size of the AP2IX-4HA protein to be 112 kDa taking into 
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Figure 14: Complementation of the AP2IX-4 knockout. Top panel (A). 
Schematic illustrating the generation of the complemented knockout (Δap2IX-
4::AP2IX-4HA). A cDNA-derived version of AP2IX-4 tagged at the C-terminus 
with 3xHA (complementation construct) was targeted to the ablated genomic 
locus in Δap2IX-4 parasites. Bottom left panel (B). Genomic PCRs with 
indicated primer pairs were performed to confirm proper integration of the 
complementation construct into Δap2IX-4 parasites. Primers to GAPDH were 
used as a positive control of the DNA preparation. Bottom right panel (C). 
Western blot of Δap2IX-4 and Δap2IX-4::AP2IX-4HA parasites with anti-HA, 
using anti-β-tubulin as a control to verify the presence of parasite protein. 
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account the three tandem HA epitopes. In addition, IFA analysis of the 
complemented knockout line demonstrates that AP2IX-4HA in tachyzoites is 
properly localized to the nucleus and matches the cell cycle-regulated pattern we 
observed in the type I parasites containing endogenously tagged AP2IX-4, 
whereby peak expression occurs during the S-M phase of the cell cycle (Figures 
11 and 15). Together, these data confirm the fidelity of the complemented 
knockout and uncover no differences in localization or cell cycle regulation of 
AP2IX-4 between type I and type II strains. 
 
 
 
Figure 15: Expression of AP2IX-4 in ∆ap2IX-4::AP2IX-4HA tachyzoites.  
IFAs were performed on Δap2IX-4::AP2IX-4HA tachyzoites as described in 
Figure 11. AP2IX-4HA was detected using anti-HA (green). To monitor cell 
cycle phases, parasites were co-stained with anti-IMC3 (red) and DAPI (blue). 
G1, gap phase; S, synthesis phase; M, mitotic phase; C, cytokinesis. Scale bar 
= 3 microns. 
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To study the expression of AP2IX-4HA in bradyzoites, ∆ap2IX-4::AP2IX-4HA 
parasites were examined at two-day intervals during bradyzoite-induction (Figure 
16A, performed by postdoctoral fellow Michael Holmes). Parasites were 
subjected to alkaline stress for two, four, six and eight days. For comparison, an 
IFA was also performed on the transgenic line under tachyzoite conditions. 
Dolichos lectin staining was performed to identify the cysts encasing the 
bradyzoites. AP2IX-4HA expression was detected in a subset of the cysts in the 
culture and localized to the bradyzoite nucleus. In addition, AP2IX-4HA expression 
was heterogeneous and confined to a subset of the bradyzoites within each cyst. 
Although the proportion of cysts containing at least one parasite expressing 
AP2IX-4HA increased from day two through day eight of bradyzoite differentiation, 
only 16% of the total number of bradyzoites within each cyst expressed AP2IX-
4HA. This suggested the possibility that the factor may be expressed in the subset 
of parasites that are dividing within the cyst. To test this idea, we co-stained anti-
HA with IMC3 (Figure 16B). The IMC3 co-stain revealed that parasites 
expressing AP2IX-4HA are in the process of forming budding daughter cells. In 
addition, the presence of AP2IX-4HA was accompanied by GFP expression that 
was driven ectopically under the bradyzoite-specific LDH2 promoter in these 
parasites. Together, these observations suggest that AP2IX-4HA expression 
continues to be cell cycle-regulated during encystation and that its expression is 
present within dividing parasites that express the GFP bradyzoite marker.  
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Figure 16. Expression of AP2IX-4 in developing bradyzoites in vitro.  
Top panel (A). IFAs were performed on ∆ap2IX-4::AP2IX-4HA parasites 
during tachyzoite and developing bradyzoite stages up to 8 days in alkaline 
pH. FITC-conjugated Dolichos lectin was used to visualize bradyzoite cyst 
walls (the LDH2-GFP reporter also appears in bradyzoites in this channel). 
AP2IX-4HA protein was visualized using anti-HA (red) and DAPI (blue) was 
used to stain DNA. For each time point, 100 random vacuoles were 
examined and scored as Dolichos positive (DOL+) if it had a complete ring 
around the cyst, and HA positive if at least one parasite within the vacuole 
had a signal. Values represent the average and standard deviation for 3 
independent experiments. Bottom panel (B). IFAs performed with anti-
IMC3 antibody (yellow) on ∆ap2IX-4::AP2IX-4HA parasites following 4 days 
in alkaline pH. The LDH2-GFP reporter (green) identifies bradyzoites. 
AP2IX-4HA protein was visualized using anti-HA (red) and DAPI (blue) was 
used to stain DNA. Arrowheads point to budding daughter cells in dividing 
bradyzoites expressing AP2IX-4HA. Scale bar = 3 microns. 
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VI. Deletion of AP2IX-4 reduces in vitro bradyzoite cyst efficiency 
We next compared the frequency of bradyzoite cyst development in PruQ 
and ∆ap2IX-4 parasites grown in alkaline induction conditions for four days. We 
employed staining with Dolichos biflorus lectin to identify bradyzoite cyst walls, 
recording the number of positive-staining cysts in 100 vacuoles sampled 
randomly. After four days in alkaline pH, 73% of parental PruQ parasites 
converted into bradyzoites, but this was reduced to 46% in parasites lacking 
AP2IX-4 (Figure 17). Complementation of the AP2IX-4 knockout parasites 
restored the rate of bradyzoite cyst formation to levels matching the parental 
PruQ strain. These data show that ablation of AP2IX-4 impairs the frequency at 
which cysts form in vitro. 
 
Figure 17. Loss of AP2IX-4 results in lower frequency of bradyzoite cyst 
formation in vitro. Parental PruQ, Δap2IX-4, and Δap2IX-4::AP2IX-4HA 
parasites were cultured in alkaline medium for 4 days and then stained with 
Dolichos lectin to visualize tissue cyst walls. For each sample, 100 random 
vacuoles were surveyed for the presence or absence of lectin staining to 
determine frequency of cyst formation. N=4 for parental and Δap2IX-4; N=3 for 
Δap2IX-4::AP2IX-4HA. * denotes p=0.04, ** denotes p=0.006, unpaired two-
tailed Student’s t-test. Error bars represent standard error of the mean. 
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VII. Analysis of Δap2IX-4 in mouse models of acute and chronic 
toxoplasmosis 
To determine the role of AP2IX-4 in in vivo pathogenesis, female Balb/c 
mice were infected with either PruQ, ∆ap2IX-4 or ∆ap2IX-4:AP2IX-4HA parasites 
and monitored daily for survival for up to two weeks. In this acute virulence study, 
inocula of 107, 106, and 105 parasites were employed to encompass the highly 
lethal (107), intermediate (106) and sub-lethal (105) dosages. By day six post-
injection, at least 75% of mice infected with 107 parasites for all strains had 
perished (Figure 18A). At the end of the study, there was no significant 
difference in survival between mice infected 107 PruQ, ∆ap2IX-4 or ∆ap2IX-
4:AP2IX-4HA parasites. All mice infected with each of the three strains at a 
dosage of 105 parasites survived the course of acute infection. However, while 
five mice died in both groups of mice infected with 106 PruQ or 106 ∆ap2IX-
4:AP2IX-4HA parasites, all mice infected with 106 ∆ap2IX-4 parasites survived 
(Figure 18A). This suggests that the loss of ap2IX-4 confers a modest virulence 
defect in ∆ap2IX-4 parasites.    
To determine the role of AP2IX-4 in cyst development in vivo, a chronic 
infection study was performed independently using four mice per group infected 
with either 106 PruQ parental, ∆ap2IX-4, or ∆ap2IX-4::AP2IX-4HA tachyzoites. 
Mice infected with parental parasites contained an average of 169 brain cysts 
while those infected with Δap2IX-4 yielded a significantly reduced average of 91 
brain cysts. Complementation of Δap2IX-4 reversed the phenotype, producing an 
average of 176 brain cysts (Figure 18B). Consistent with the reduced frequency 
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of bradyzoite development noted in vitro, these data suggest that loss of AP2IX-4 
also results in decreased bradyzoite frequency in vivo.    
A virulence defect in the ∆ap2IX-4 parasites as observed in the acute 
virulence study (Figure 18A) may impact cyst frequency in vivo. For example, 
the decreased virulence in ∆ap2IX-4 parasites may reduce the number of 
parasites successfully initiating bradyzoite development in the brains of the mice. 
Therefore, survivors of the acute infection phase of the experiment were 
sacrificed at day 35 and their brains harvested. The three surviving mice in the 
PruQ-infected group demonstrated an average cyst burden of 2,652 cysts, while 
the eight mice surviving in the ∆ap2IX-4 group demonstrated significantly 
reduced average cyst burden of 711 (Figure 18C). Thus, the reduction in cyst 
burden in the brains of ∆ap2IX-4-infected acute virulence survivors is consistent 
with the reduction observed in the independent chronic infection study.  
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Figure 18. Role of AP2IX-4 in acute and chronic infection in Balb/c mouse 
model. Top panel (A). Eight mice in each of three groups were infected with 
either the PruQ parental, ∆ap2IX-4 or ∆ap2IX-4::AP2IX-4HA parasites in an 
experiment performed with either 107, 106 or 105 dosages. * denotes p=0.01; ** 
denotes p=0.02, log-rank test. Bottom panel (B). The chronic infection study 
was performed independently using four mice per group infected with either 
106 PruQ parental, ∆ap2IX-4, or ∆ap2IX-4::AP2IX-4HA parasites. Brains of 
mice were harvested at day 35 post-infection and homogenized for preparation 
of IFA samples. Cysts were detected using Dolichos lectin staining. Horizontal 
bars on graphs denote cyst number averages. * denotes p=0.03, unpaired 
one-tailed Student’s t-test. 
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(CONTINUED) Figure 18. Role of AP2IX-4 in acute and chronic infection 
in Balb/c mouse model. (C). Brains of survivors infected with 106 parasites in 
the acute virulence study (Figure 18A) were harvested at day 35 post-injection 
for evaluation of cyst burden. Horizontal bars denote cyst number averages. * 
denotes p=0.049, unpaired one-tailed Student’s t-test.  
 
VIII. Loss of AP2IX-4 results in enhanced bradyzoite gene expression  
To study how AP2IX-4 impacts the parasite transcriptome in response to 
alkaline stress, we collaborated with Drs. Joshua Radke and Dong-Pyo Hong 
(Michael White Lab, University of South Florida) to perform a microarray analysis 
on PruQ, ∆ap2IX-4 and ∆ap2IX-4::AP2IX-4HA parasites cultured in either 
tachyzoite (pH 7.6) conditions or 48 hours in bradyzoite (pH 8.2) conditions. Total 
RNA of cultured parasites was prepared in our laboratory, and generation of 
hybridization probes for the ToxoGeneChip and statistical analyses were 
performed by the White Lab.  
Only 24 genes were differentially expressed two-fold or more between 
PruQ and ∆ap2IX-4 parasites under tachyzoite conditions (Table 4). Three genes 
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(TGME49_239580, TGME49_312905, and TGME49_312905) encoding genes of 
hypothetical function, were upregulated in the ∆ap2IX-4 compared to parental 
parasites. The rest of the genes were downregulated. These included bradyzoite 
surface antigens or cyst wall proteins such as MCP4, SRS35A/SAG4.2, and 
SRS13.The presence of bradyzoite proteins in tachyzoites may help “poise” the 
parasites for efficient differentiation; decreased expression of these proteins in 
the AP2IX-4 knockout tachyzoites could partly explain the diminished numbers of 
cysts in response to alkaline stress. 
In contrast, under bradyzoite conditions, a total of 119 genes were 
differentially expressed two-fold or more between PruQ and ∆ap2IX-4 parasites. 
64 were downregulated in the Δap2IX-4 compared to the parental while 55 were 
upregulated. Approximately 89% of these genes were complemented in knockout 
parasites in which AP2IX-4 expression had been restored. Further discussion is 
limited to genes that exhibited >1.5-fold restoration of gene expression in 
complemented parasites relative to the knockout (Table 5). By this stringent 
criteria, 20 of the downregulated genes (including AP2IX-4) and 34 of the 
upregulated genes were complemented.   
Four bradyzoite-associated genes were downregulated in the knockout 
following alkaline stress. These included enoyl coA hydratase/isomerase, and 
hypothetical proteins TGME49_205680, TGME49_287040, and 
TGME49_306270 (Table 5). Enoyl coA hydratase/isomerase, along with a MoeA 
domain-containing protein (involved in biosynthesis of molybdopterin), were 
downregulated in the AP2IX-4 knockout in both tachyzoite and bradyzoite-
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inducing conditions. The majority of genes showing upregulated expression in 
the AP2IX-4 knockout upon stress were those encoding well-established 
bradyzoite-associated proteins such as ENO1, BAG1, PMA1, B-NTPase, LDH2, 
DnaK-TPR, SAG2C, and MCP4 (Table 5). A previously uncharacterized 
bradyzoite-specific CMGC kinase MAPK family (TGME49_221550) was also 
upregulated in the AP2IX-4 knockout. 
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Table 4. Differentially expressed genes (FC≥2) under tachyzoite conditions 
in PruQ∆ap2IX-4 compared to parental PruQ parasites. 
 
 
 
Probe Set ID 
 
 
Gene 
 
 
Annotation 
PruQ∆ap2IX-4  
vs. PruQ Parental 
(FC) 
80.m02181_at TGME49_288950 AP2IX-4 -32.9 
611.m00052_at TGME49_317705 enoyl-CoA 
hydratase/isomerase family 
protein 
-5.7 
55.m00162_at TGME49_261650 hypothetical protein -4.7 
83.m01216_at TGME49_293480 MoeA N-terminal region 
(domain I and II) domain-
containing protein 
-4.3 
25.m01822_at TGME49_208730 microneme protein, putative; 
MCP4 
-3.9 
551.m00220_at TGME49_307760 tubulin-tyrosine ligase family 
protein 
-3.3 
31.m00936_at TGME49_212940 hypothetical protein -3.2 
20.m00337_at TGME49_203720 vitamin K epoxide reductase 
complex subunit 1 
-3.2 
37.m00739_at TGME49_217400 hypothetical protein -3.2 
641.m00181_at TGME49_320740 hypothetical protein -3.0 
23.m00155_at TGME49_207210 hypothetical protein -3.0 
72.m00004_at TGME49_280570 SAG-related sequence 
SRS35A (SRS35A) aka 
bradyzoite surface antigen 
(SAG4.2, p18) 
-2.8 
541.m02517_at TGME49_304930 hypothetical protein -2.7 
25.m00212_at TGME49_208740 microneme protein, putative -2.5 
50.m03090_at TGME49_245770 hypothetical protein -2.5 
80.m02369_s_at TGME49_292375 KRUF family protein -2.4 
94.m00031_s_at TGME49_296340 hypothetical protein -2.2 
76.m01568_s_at TGME49_284420 hypothetical protein -2.2 
41.m01360_at TGME49_222370 SAG-related sequence 
SRS13 (SRS13) 
-2.2 
55.m04865_at TGME49_260190 microneme protein MIC13 
(MIC13) 
-2.2 
49.m03275_at TGME49_242110 Rhoptry kinase family 
protein ROP38 
-2.2 
55.m00276_at TGME49_255210 ATPase, AAA family protein -2.1 
52.m00020_at TGME49_253710 hypothetical protein -2.1 
49.m03157_at TGME49_239580 hypothetical protein 4.6 
583.m00678_at TGME49_312905 hypothetical protein 3.8 
583.m00665_at TGME49_312905 hypothetical protein 2.3 
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Table 5. Differentially expressed genes (FC>2) in ∆ap2IX-4 and ∆ap2IX-
4::AP2IX-4HA during bradyzoite induction conditions. 
 
Highlighted in gray are genes previously found to be expressed during the 
bradyzoite stage (See Chapter 2 Section IV.C).  
 
Accession no. Annotation 
PruQ∆ap2IX-4  
vs. PruQ 
parental (FC) 
∆ap2IX-4::AP2IX-4HA  
vs PruQ∆ap2IX-4 (FC) 
 
 
DOWNREGULATED GENES  
 
TGME49_288950 AP2IX-4 -38.1 22.00 
TGME49_319890 hypothetical protein -7.6 1.8 
TGME49_293480 
MoeA N-terminal region (domain I and 
II) domain-containing protein -7.4 
3.4 
TGME49_243940 hypothetical protein -7.0 1.8 
TGME49_204050 subtilisin SUB1 (SUB1) -4.9 1.7 
TGME49_317705 enoyl coA hydratase/isomerase -3.8 2.2 
TGME49_297910 hypothetical protein -3.7 2.1 
TGME49_256792 hypothetical protein -3.6 2.1 
TGME49_217400 hypothetical protein -3.5 3.2 
TGME49_205680 hypothetical protein -3.2 1.7 
TGME49_287040 hypothetical protein -3.1 1.8 
TGME49_306270 hypothetical protein -3.0 1.7 
TGME49_280500 
inorganic anion transporter, sulfate 
permease (SulP) family protein -2.6 
 
2.2 
TGME49_261250 histone H2A1 -2.6 1.7 
TGME49_240090 
rhoptry kinase family protein ROP34, 
putative -2.5 
1.6 
TGME49_214190 SRS46 -2.3 1.6 
TGME49_239260 histone H4 -2.2 1.7 
TGME49_261240 histone H3 -2.1 2.4 
TGME49_305160 histone H2Ba -2.0 2.9 
TGME49_255060 
cytochrome b(N-terminal)/b6/petB 
subfamily protein -2.0 
3.9 
 
Note: Table 5 (upregulated genes) continued on next page 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
(CONTINUED) Table 5 
 
Accession no. Annotation 
PruQ∆ap2IX-4  
vs. PruQ 
parental (FC) 
∆ap2IX-4::AP2IX-4HA  
vs PruQ∆ap2IX-4 (FC) 
 UPREGULATED GENES   
TGME49_268860 ENO1 10.2 -2.3 
TGME49_312905 hypothetical protein 9.7 -7.3 
 TGME49_209755 hypothetical protein 7.0 -2.5 
TGME49_259020 BAG1  5.7 -1.6 
TGME49_293790 hypothetical protein 4.9 -2.1 
TGME49_278080 Toxoplasma gondii family A protein 4.9 -1.7 
TGME49_216140 
tetratricopeptide repeat-containing 
protein 4.4 
-1.8 
TGME49_252640 P-type ATPase PMA1 4.4 -1.7 
TGME49_225290 
GDA1/CD39 (nucleoside phosphatase) 
(B-NTPase) 4.1 
-2.1 
TGME49_315560 
ATP-binding cassette G family 
transporter ABCG77 4.0 
-1.5 
TGME49_291040 lactate dehydrogenase LDH2 (LDH2) 4.0 -1.6 
TGME49_202020 DnaK-TPR 3.9 -1.8 
 TGME49_221550 
CMGC kinase, MAPK family, MEK 
kinase-related 3.7 
 1.9 
 TGME49_292260 
SAG-related sequence SRS36B 
(SAG5D) 3.6 
-1.9 
 TGME49_266700 hypothetical protein 3.5 -1.9 
 TGME49_240470 hypothetical protein 3.2 -1.7 
 TGME49_207160 
SAG-related sequence SRS49D 
(SAG2C) 3.1 
-2.2 
 TGME49_267470 
cold-shock DNA-binding domain-
containing protein 3.1 
-1.7 
TGME49_253680 hypothetical protein 3.0  1.5 
TGME49_208730 microneme protein, putative (MCP4) 3.0 -1.6 
TGME49_207150 
SAG-related sequence SRS49C 
(SAG2D) 2.9 
-1.9 
TGME49_287960 hypothetical protein 2.7 -1.6 
TGME49_218470 protein disulfide-isomerase 2.6  1.9 
TGME49_253710 hypothetical protein 2.6 -1.7 
TGME49_306338 
dynein gamma chain, flagellar outer arm, 
putative 2.5 
-1.9 
TGME49_243720 
peroxisomal biogenesis factor PEX11 
(PEX11) 2.5 
-1.9 
TGME49_259960 nucleoside-diphosphatase 2.4 -1.5 
TGME49_312905 hypothetical protein 2.4 -2.0 
TGME49_314250 bradyzoite rhoptry protein BRP1 (BRP1) 2.4 -1.8 
TGME49_253330 rhoptry kinase family protein (BPK1) 2.3 -1.5 
TGME49_224830  hypothetical protein  2.2  1.5 
TGME49_221840  hypothetical protein 2.2 -1.5 
TGME49_311370 
methylmalonate-semialdehyde 
dehydrogenase 2.1 
-2.0 
TGME49_213460 hypothetical protein 2.0 -1.7 
TGME49_266900 
Cyclin, N-terminal domain-containing 
protein 2.0 
-1.6 
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IX. Strategies to generate overexpression of AP2IX-4 
Attempts were made to generate parasites that express AP2IX-4 ectopically 
under the constitutively active tubulin promoter. Two separate plasmid constructs 
were designed, one with AP2IX-4 tagged at its C-terminus with three tandem HA 
tags and another with AP2IX-4 tagged at its N-terminus (Figure 19). Both 
constructs were sequenced and shown to be in-frame with the HA tags. Both the 
C- and N-terminus HA-tagged lines demonstrated similar phenotypes of slow 
growth, with the slowest growers taking more than two weeks to fully lyse a 
monolayer. The morphology of the parasites within their vacuoles was abnormal 
for both parasite lines, appearing round instead of banana-shaped, with 
abnormal numbers of parasites within the vacuoles (Figure 19). IFA with anti-HA 
showed the recombinant AP2IX-4 to be diffuse throughout the parasite. No 
further phenotypic experiments were pursued with these lines since the ectopic 
AP2IX-4 was mis-expressed in the parasite cytosol.  
 
X. Yeast two-hybrid screen uncovers AP2IX-4 protein interactors  
We performed a yeast two-hybrid screen using the entire AP2IX-4 coding 
sequence as bait to identify interacting proteins. The prey library was constructed 
from RH strain total RNA generated in our laboratory, and library construction 
and screening were performed by Hybrigenics Services (https://www.hybrigenics-
services.com/; see Chapter 2 Section VI). 
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The list of all T. gondii AP2IX-4 interactors identified through the yeast 
two-hybrid screen is summarized in Table 6. Several proteins in the list of 
potential interactors are most likely false positive interactions based on functional 
characterizations and localizations of these and similar proteins: myosin light 
chain MLC1 (TGME49_257680), histidyl-tRNA synthetase (HisRS) 
(TGME49_280600), rhoptry neck protein RON5 (TGME49_311470), microneme 
protein MIC15 (TGME49_247195), and ATP-citrate lyase (TGME49_223840) 
(180-182). In addition, three interactions occurred with proteins from the human 
proteome, and this is most likely the result of human cDNAs in the prey library 
representing low levels of contamination with total RNA from the HFFs in which 
 
Figure 19. Expression of AP2IX-4 under constitutive tubulin promoter 
results in mis-expression. AP2IX-4 was appended with tandem HA tags at 
either its N- or C-terminus and cloned for expression under the tubulin 
promoter.  
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the parasites were grown (see Appendix for complete list of all yeast two-hybrid 
interactions and corresponding PBS scores).  
Among the list of interacting proteins are five AP2 proteins: AP2X-9, 
(TGME49_215150), AP2XII-1 (TGME49_218960), AP2VIIa-8 
(TGME49_282210), AP2X-11 (TGME49_215570) and AP2X-2 
(TGME49_225110). The microarray data assessing transcript levels of these 
AP2s through the tachyzoite cell cycle demonstrates that the transcripts for the 
first four of these AP2 proteins all exhibit cell cycle regulation with peak 
expression at the S/M phase (Toxodb.org; 109). The cell cycle transcript data for 
AP2X-2 is unavailable from Toxodb.org. Therefore, the temporal regulation of the 
four AP2s whose cell cycle transcript data is available is consistent with the cell 
cycle regulation of AP2IX-4 and should be confirmed with evaluation of protein 
expression through the tachyzoite cell cycle. In addition, the interaction of AP2IX-
4 with other AP2s is consistent with the passive repressor model by which plant 
AP2 and other eukaryotic transcriptional repressors operate (see Discussion). 
Reciprocal interactions of these AP2IX-4 should be validated in co-
immunoprecipitation. These AP2s are promising candidates for further studies as 
they provide clues to the mechanism of AP2IX-4 on gene expression and 
bradyzoite biology. A remaining question is whether AP2IX-4 interacts with these 
AP2s during the tachyzoite cell cycle, during bradyzoite development, or both 
stages.  
 Another AP2IX-4 interactor, TGME49_311400, contains a MAPK-
interacting and spindle-stabilizing protein-like (MISS) domain that includes MAPK 
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phosphorylation sites. In mouse oocytes, the MISS protein is a MAPK substrate 
that maintains spindle integrity during meiosis. The protein also contains a WD40 
domain; in higher eukaryotes WD40 repeat proteins are involved in diverse 
cellular processes, including nucleosome and chromatin organization and 
transcriptional regulation (179).  
AP2IX-4 also interacted with an ImpB/MucB/SamB family protein 
(TGME49_ TGME49_308880) that belongs to the DNA polymerase type-y family 
involved in response to DNA lesions. Among other interesting candidates from 
the yeast two-hybrid results is TGME49_320300, a SWI2/SNF2 Brahma-like 
putative that may represent a putative chromatin remodeling protein important for 
AP2IX-4 transcriptional function. TGME49_294610 is predicted to encode a SET-
domain containing lysine methyltransferase whose interaction with AP2IX-4 
should also be validated and examined, as this class of proteins may either 
activate or repress gene expression depending on which lysine residue they 
modify.   
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Table 6. Protein interactors of AP2IX-4 from yeast two-hybrid screen 
 
Gene Annotation 
TGME49_246340 DnaJ domain-containing protein 
TGME49_215150 AP2X-9 
TGME49_257680 myosin light chain MLC1 
TGME49_280600 histidyl-tRNA synthetase (HisRS) 
TGME49_218960 AP2XII-1 
TGME49_282210 AP2VIIa-8 
TGME49_311400 WD domain, G-beta repeat-containing protein 
TGME49_213067 hypothetical protein 
TGME49_311470 rhoptry neck protein RON5 
TGME49_247195 microneme protein MIC15 
TGME49_239910 cyclin-dependent kinase 
TGME49_263060 Proteasome/cyclosome repeat-containing protein 
TGME49_223840 ATP-citrate lyase 
TGME49_308880 ImpB/MucB/SamB family protein 
TGME49_288240 hypothetical protein 
TGME49_224970 nucleolar protein 
TGME49_215570 AP2X-11 
TGME49_234990 hypothetical protein 
TGME49_239885 hypothetical protein 
TGME49_293320 hypothetical protein 
TGME49_212190 RNA recognition motif-containing protein 
TGME49_320300 
TGME49_270595 
SWI2/SNF2 Brahma-like putative 
UBA/TS-N domain-containing protein 
TGME49_288700 RecF/RecN/SMC N terminal domain-containing protein 
TGME49_304990 guanylate-binding protein 
TGME49_280600 histidyl-tRNA synthetase (HisRS) 
TGME49_314410 aquarius 
TGME49_225110 AP2X-2 
TGME49_212300 hypothetical protein 
TGME49_294610 histone lysine methyltransferase, SET 
TGME49_287480 hypothetical protein 
TGME49_304630 ATG C terminal domain-containing protein 
TGME49_213020 hypothetical protein 
TGME49_306320 Myb family DNA-binding domain-containing protein 
TGME49_261660 hypothetical protein 
TGME49_270930 hypothetical protein 
TGME49_222350 hypothetical protein 
TGME49_230000 hypothetical protein 
TGME49_250700 hypothetical protein 
TGME49_275430 
TGME49_272155 
hypothetical protein 
hypothetical protein 
TGME49_245990 hypothetical protein 
TGME49_264830 hypothetical protein 
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TGME49_231200 hypothetical protein 
TGME49_286270 hypothetical protein 
TGME49_294060 hypothetical protein 
TGME49_261960 hypothetical protein 
TGME49_290678 hypothetical protein 
TGME49_312630 anonymous antigen-1 
TGME49_312190 hypothetical protein 
TGME49_212880 surface antigen repeat-containing protein 
TGME49_254710 serine esterase (DUF676) protein 
TGME49_227450 hydrolase, NUDIX family protein 
TGME49_221640 hypothetical protein 
TGME49_244450 protein phosphatase 2C domain-containing protein 
TGME49_264880 NEDD8-activating enzyme E1 catalytic subunit 
TGME49_294690 rhomboid protease ROM5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
CHAPTER 4: DISCUSSION 
This thesis described the characterization of AP2IX-4, a novel member of 
the AP2 class of DNA-binding proteins in T. gondii. AP2IX-4 contains one 
putative AP2 DNA-binding domain. Microarray data suggested that the transcript 
expression of this factor peaked at the S/M phase of the tachyzoite cell cycle and 
is upregulated in response to alkaline stress (103, 156). AP2IX-4 transcript 
expression is also elevated during chronic infection of mice (159). From these 
observations, we hypothesized that AP2IX-4 is a cell cycle-regulated 
transcription factor that contributes to the biology of bradyzoite cysts.  
To address this hypothesis, we examined AP2IX-4 protein expression 
during the parasite tachyzoite and bradyzoite stages and generated a knockout 
of this factor to study its role in tachyzoite replication and bradyzoite 
development. To assess the effect of AP2IX-4 on gene modulation, we 
performed microarray analysis to compare gene expression in AP2IX-4 knockout 
and parental parasites under both tachyzoite and bradyzoite conditions. Finally, 
we initiated a yeast two-hybrid study to screen for AP2IX-4 interactors. Our 
results showed that AP2IX-4 is expressed in both dividing tachyzoites and 
dividing bradyzoites.  In response to alkaline stress, ∆ap2IX-4 parasites exhibited 
reduced frequency of cysts accompanied by enhancement of the expression of  
bradyzoite-associated genes. In vivo, ∆ap2IX-4 parasites demonstrated a modest 
virulence defect that was accompanied by decreased cyst burden in the brains of 
Balb/c mice.  
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    I.       AP2IX-4 is a nuclear factor expressed in the S/M phase of the     
             tachyzoite cell cycle, but is dispensable for tachyzoite replication.  
To compare AP2IX-4 protein expression to transcript data, we generated a 
parasite line in which AP2IX-4 was tagged at its C-terminus with three tandem 
HA tags. IFAs employing anti-HA and DAPI revealed the presence of AP2IX-4 in 
the parasite nucleus, a result consistent with the role of this factor as a putative 
transcription factor. Co-staining with IMC3 demonstrated that AP2IX-4 is 
expressed predominantly in the S through M phases of the tachyzoite cell cycle, 
which is consistent with its transcript data. Therefore, we demonstrated that 
AP2IX-4 is a cell cycle-regulated nuclear factor.  
The “just-in-time” expression of AP2IX-4 in dividing tachyzoites suggests it 
may be important in tachyzoite replication. Therefore, to examine the role of 
AP2IX-4 in tachyzoite replication and viability, we generated a knockout of this 
factor. Parasite replication rates were assessed using a doubling assay, and 
viability was evaluated using a plaque assay. Neither assay revealed a significant 
difference in the in vitro growth between parental and Δap2IX-4 parasites.  
In tachyzoites, daughter cell formation begins in the late S phase, and 
nuclear and organelle partitioning are concurrent and terminate in the generation 
of daughter parasites in cytokinesis. Yet, the replication and viability data 
demonstrates that AP2IX-4 is not essential for tachyzoite replication. To date, 
only one other publication assessed the knockout of a cell cycle-regulated AP2. 
A knockout of AP2XI-5, whose transcript expression peaks during mitosis and 
cytokinesis, was generated in both type I and type II strains and neither 
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demonstrated a growth defect (158). Interestingly, knockout of AP2XI-5 in type II 
Pru reduced brain cyst burden in mice (158). This suggests that cell cycle-
regulated factors in T. gondii may not necessarily direct replication in the 
tachyzoite stage but may play important roles in bradyzoite development.  
As mentioned in the introduction, parasites positive for both tachyzoite and 
bradyzoite markers appear at the junction of the S and mitotic phases of the 
tachyzoite cell cycle (108). The appearance of these parasites precedes 
appearances of BAG1-positive and SAG1-negative parasites, suggesting that the 
S/M phase may be a point of commitment to bradyzoite development. Therefore, 
peak protein expression of AP2IX-4 may relate to its potential function in 
bradyzoite biology instead of a dominant role in tachyzoite replication. The 
negative tachyzoite data on tachyzoite replication and viability combined with the 
association of the S/M phase in bradyzoite development encouraged us to focus 
on the role of AP2IX-4 in bradyzoite development. 
 
II. AP2IX-4 is expressed in dividing bradyzoites.  
To begin dissecting the role of AP2IX-4 in bradyzoite development, we 
examined the expression of this factor under bradyzoite induction conditions. 
IFAs were performed using ∆ap2IX-4::AP2IX-4HA parasites, a type II Pru line 
which expressed AP2IX-4 with three tandem HA tags in its C-terminus, under 
alkaline conditions using DAPI and anti-HA staining. This experiment revealed 
four key observations. First, AP2IX-4 is expressed in the nuclei of bradyzoites, 
consistent with a putative role as a transcription factor. Second, unlike its 
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expression in all parasites within a subset of tachyzoite vacuoles, AP2IX-4 is 
expressed in only 16% of parasites contained in a subset of cysts. Third, IMC3 
co-staining with HA demonstrated that AP2IX-4 is expressed in dividing 
bradyzoites. This is a novel finding as AP2IX-4 is the first AP2 to be found 
expressed in both dividing tachyzoites and bradyzoites.  
Lastly, the presence of budding daughter cells in parasites expressing HA-
tagged AP2IX-4 was found alongside expression of GFP, which in these 
parasites was expressed under the bradyzoite-specific LDH2 promoter. 
Together, these observations indicate heterogeneity of AP2IX-4 expression 
within the cyst and that it is expressed in parasites that are dividing yet express a 
bradyzoite marker.  
The heterogeneity of AP2IX-4 expression is consistent with emerging data 
showing that bradyzoites within a cyst are dynamic, dividing entities. Varying 
stages of daughter cell assembly has been observed among bradyzoites in a 
cyst (180, 181). In vivo, dividing and non-dividing parasites can be observed 
within a cyst, with dividing parasites exhibiting two patterns of IMC3 staining 
derived from asynchronous division of parasites within a cyst (181). Populations 
of parasites within a cyst can exhibit “cluster” replication, in which groups of 
parasites in close vicinity appear to exhibit buddying daughter cell formation at 
the same time (181). This is in comparison to “sporadic” replication, in which 
isolated parasites scattered throughout the cyst exhibit division (181). 
Synchronized replication, in which all parasites within the cyst exhibit robust 
IMC3 staining, has also been observed. Furthermore, the number of cysts 
111 
containing asynchronously dividing parasites increases in the time course of 
bradyzoite development (180). Our observation that AP2IX-4 is expressed in 
asynchronously dividing bradyzoites and that the number of vacuoles positive for 
AP2IX-4 increases through bradyzoite development further supports the 
heterogeneous nature of dividing bradyzoites within tissue cysts.  
The expression of AP2IX-4 in dividing and GFP-positive bradyzoites is 
consistent with emerging data that illustrate bradyzoite development as occurring 
through multiple transitions. Preceding the progression to the mature bradyzoite 
are events linking the tachyzoite cell cycle with commitment to differentiation, 
whereby the tachyzoite cell cycle lengthens and growth rate decreases 
accompanied by the enrichment of a population of parasites with DNA content of 
1.8-2N (38, 107, 108). These G2/S phase parasites are both SAG1 and BAG1-
positive (108). A developing bradyzoite cyst may contain parasites exhibiting 
bradyzoite-specific, tachyzoite-specific or bradyzoite and tachyzoite-specific 
markers (106, 182). Gene expression data also support the view of the cyst as 
developing in a temporal cascade of bradyzoite expression (103, 117, 118).  
While the expression of AP2IX-4 in bradyzoites is consistent with existing 
literature demonstrating transitioning and dividing bradyzoites within a cyst, 
further questions remain due to missing links in bradyzoite biology knowledge. Of 
note, while existing literature suggests that bradyzoite development occurs in a 
step-wise, multi-transition manner, the role of bradyzoite division in this process 
is unclear. AP2IX-4 may be a useful candidate for uncovering more of bradyzoite 
biology by dissecting the purpose of bradyzoite division in this multi-step process. 
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Therefore it serves as a useful marker of transitioning bradyzoites, and the role of 
AP2IX-4 in bradyzoite transition and division remains to be elucidated in future 
studies.  
 
III. Ablation of AP2IX-4 decreased cyst frequency in alkaline 
induction and in brains of chronically infected mice.   
The presence of AP2IX-4 in bradyzoites suggest it plays a role in 
bradyzoite development. We therefore subjected PruQ and ∆ap2IX-4 parasites to 
differentiation assays, in which parasite cultures were grown in alkaline 
conditions for four days before they were stained with Dolichos bifluorus lectin to 
mark bradyzoite cyst walls. These differentiation assays revealed that 73% of 
PruQ vacuoles exhibited lectin staining compared to 46% in ∆ap2IX-4 parasite 
cultures. Consistent with the reduction in cyst frequency observed in vitro in 
∆ap2IX-4 parasite cultures, we observed a reduction in cyst burden in the brains 
of mice infected with ∆ap2IX-4 parasites. This suggests that AP2IX-4 contributes 
to the frequency of lectin-positive cysts. However, the exact role AP2IX-4 exerts 
in bradyzoite biology remains to be dissected, and future in vitro studies should 
be undertaken to address the following questions:   
- What is the role of AP2IX-4 in dividing parasites within the alkaline-
induced cyst?  
- How does the dysregulation of gene expression in ∆ap2IX-4 parasites 
result in decreased cyst frequency in vitro and in vivo? 
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- Where in the genome (such as gene-specific cis-regulatory sequences, 
intergenic regions, and introns) does AP2IX-4 localize and enrich? What 
are AP2IX-4 interactors and do these interactors impact bradyzoite 
biology?  
 
IV. AP2IX-4 as a transcriptional repressor of a subset of bradyzoite-
associated genes.  
Following the initial commitment to bradyzoite differentiation at the S/M 
phase of the tachyzoite cell cycle, the gradual maturation of the cyst is based 
upon a temporal cascade or gene expression, whereby bradyzoite-specific genes 
are turned on step-wise in the development time course (103, 117, 118). BAG1 
mRNA expression has been consistently demonstrated to be induced around day 
three of differentiation, later than the induction of other bradyzoite markers such 
as ENO1 and LDH2 (117, 118). Although the molecular mechanisms underlying 
progression from the early to late bradyzoite remain to be fully elucidated, Radke 
et al. proposed a model employing data on AP2IX-9, whose expression in 
alkaline conditions is persistent only in early stage bradyzoites (156). This model 
suggests that AP2IX-9 inhibits progression of the premature bradyzoite, a 
repression that might serve useful in conditions where further development is not 
necessary or favored (156).  
Moreover, the identification of a bradyzoite development activator, AP2XI-
4, suggests that bradyzoite progression may in part occur mechanistically 
through competition between molecular activators and repressors (156, 157, 
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183). This competition mechanism is well-conserved in higher eukaryotes, in 
which the cellular decision to differentiate occurs in the G1 phase of the cell cycle 
and is mediated by the interaction between E2F transcription factors and 
activating or repressing complexes (184, 185).  AP2XI-4 was demonstrated to 
activate the expression of bradyzoite genes in addition to BAG1, while AP2IX-9 
represses the expression of BAG1 (156, 157). Together, the AP2XI-4 and AP2IX-
9 data support a model by which transcriptional activator and repressor 
complexes may compete for binding on stage-specific promoters. Future studies 
should consider our yeast two-hybrid results to elucidate AP2IX-4’s mechanism 
as a potential transcriptional repressor. 
 
 
V. Conclusions and future studies  
In reviewing our hypothesis, we first demonstrated that AP2IX-4 is a cell 
cycle-regulated nuclear factor. Second, the enhancement of bradyzoite-
associated gene expression in response to alkaline stress, combined with 
reduced cyst frequency of ∆ap2IX-4 parasites in the brains of chronically infected 
mice indicate a role for AP2IX-4 in bradyzoite biology. However, two key 
questions remain which will be evaluated in this section:  
i. What is the role of AP2IX-4 in dividing bradyzoites?  
ii. How does AP2IX-4 operate as a transcription factor, especially with 
regards to its potential repressor role?  
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i. Role of AP2IX-4 in dividing bradyzoites.  
Its expression in dividing bradyzoites in the tissue cyst suggests that 
AP2IX-4 may repress bradyzoite progression in these intermediate entities. One 
possibility, therefore, is that AP2IX-4 represses bradyzoite development in favor 
of continued parasite replication. Continued parasite replication would confer an 
advantage to the parasite by expanding parasite burden for eventual 
dissemination in the host, while maintained latency would ensure the host 
survival until the parasite is ready to disseminate.  
Another possibility is that AP2IX-4 represses both bradyzoite development 
and replication, that is, towards the goal of maintaining latency. The expression 
of this factor in the subset of bradyzoites that exhibit IMC3-positive daughter cell 
formation is appropriate, as it is possible that these dividing parasites are simply 
those in the decision process of whether to continue dividing, progress further in 
the bradyzoite progression or to pursue neither route. This model thereby 
introduces another intermediate in the bradyzoite development timeline in which 
a non-developing, latent parasite exists.  
Future Studies. Further experiments should dissect out these models:   
(1) IMC3 staining should be examined in ∆ap2IX-4 parasites cultured in 
alkaline stress. If more parasites exhibit IMC3 staining following loss of 
AP2IX-4, this supports the model in which AP2IX-4 suppresses bradyzoite 
replication, resulting in increased daughter cell formation in the knockout 
parasites.  
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(2) Increased replication of parasites lacking AP2IX-4 will also favor the 
model in which this factor is a suppressor of replication. An increased 
replication phenotype may be accompanied by increased glycolytic flux or 
oxidative phosphorylation, such as that measured by the SeaHorse XF 
Analyzer. Other phenotypes of increased parasite replication include 
acidification of alkaline medium in which the parasites are cultured.  
ii. AP2IX-4 as a transcriptional repressor.  
In our microarray performed under alkaline conditions, 22 out of 35 or 63% of 
the genes whose transcripts were upregulated in the ∆ap2IX-4 parasites are 
bradyzoite-associated, including BAG1. This suggests that AP2IX-4 may be a 
transcriptional repressor of these bradyzoite-associated genes. Since it was not 
known whether AP2IX-4 localizes to the loci of genes dysregulated in the 
microarray, we attempted ChIP-qPCR to examine whether HA-tagged AP2IX-4 
would localize to promoter regions of BAG1. The HA-tagged version of 
TgGCN5B (GCN5BHA), expressed under the tubulin promoter, was used as 
positive control (186). Two T-150cm2 flasks, each containing intracellular AP2IX-
4HA or GCN5BHA parasites, were fixed in 16% paraformaldehyde and pellets were 
subjected to sonication on ice at 30% output and six times 30s on/off. When 
sonicated genomic material from the lysates were resolved on agarose gel, the 
GCN5BHA sample revealed a DNA smear representing sonicated chromatin at 
desired sizes of 500-1000 bp. However, in all trials in the same conditions, 
sonicated genomic material from AP2IX-4HA parasites resolved as a single band 
of about 400bp. AP2IX-4 may be involved in chromatin compaction, and the HA 
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epitopes may interfere with this function. One way to test this is through a DNase 
I hypersensitivity assay as described in (187). This assay works under the 
premise that less compacted, exposed chromatin is more sensitive to DNase I 
access. Exposed chromatin can be found in transcriptionally active areas. If 
AP2IX-4 function targets it differentially to structurally compact or open 
chromatin, and epitope tagging can interfere with this function, then the DNase I 
assay may reveal differences in digested chromatin pattern in wild-type versus 
tagged parasite lines. For example, less compact chromatin may be more 
amenable to shearing by sonication such that the same sonication conditions 
which yield a smear for GCN5HA may yield the single band composed of 
uniformly shorter (~400 bp) fragments for AP2IX-4HA. 
Given that AP2 proteins contain plant-like homology, it is important to note 
that at least two models of repression by transcriptional protein complexes exist 
for plant AP2s (188). Transcriptional repressors may inhibit gene expression as 
either active or passive repressors. The mechanism of passive repressors can be 
mediated through either direct DNA binding or DNA binding-independent, 
protein-protein steric interference (189. 190). For example, passive repressors 
may interfere with transcriptional activation complexes such as by binding directly 
to DNA, thereby competing for the same DNA binding sites. They may also 
directly bind to transcriptional activators, precluding the ability of these activators 
to bind DNA and activate gene expression. Active repressors, on the other hand, 
are able to intrinsically repress gene expression such as through recruitment of 
chromatin modifying complexes.  
118 
Previous attempts to identify a DNA-binding motif for the AP2 domain of 
AP2IX-4 using protein binding microarrays (PBMs) did not reveal a potential 
DNA-binding motif. While there are limitations to this artificial approach and the 
ability of AP2IX-4 to bind to DNA cannot be completely ruled out, the data 
supports a model by which AP2IX-4 represses gene expression independent of 
DNA binding. Analysis of AP2IX-4 interactors can provide important clues on the 
mechanism of AP2IX-4 repression.  
Protein-protein interactions can be screened using various approaches, 
including co-immunoprecipitation followed by mass spectrometry or a yeast two-
hybrid assay. In the co-immunoprecipitation approach, an antibody is used to 
target and “pull-down” a protein-of-interest, whose interacting proteins are then 
resolved on a gel for subsequent identification via mass spectrometry. The major 
technical challenge with this approach is due to the limiting levels of AP2IX-4, 
which is cell cycle-regulated. Attempts to pull down sufficient amounts of AP2IX-4 
and its associating partners could be tried after synchronizing tachyzoite 
populations, in order to maximize the number in S/M where the protein 
expression peaks. We employed a yeast two-hybrid approach to overcome these 
limitations of protein concentration. With Hybrigenics Services, we performed a 
yeast two-hybrid screen to identify bait (AP2IX-4) interactions with prey 
generated from a T. gondii cDNA library. However, this is an artificial system and 
may identify false protein interactions; candidate interacting proteins will have to 
be verified through independent methods.  
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Our yeast two-hybrid results revealed interactions with five other potential 
transcriptional modulators of the AP2 class. Interestingly, the cell cycle regulation 
transcript data for four of these five revealed peak expression during the S/M 
phase. The interaction of AP2IX-4 with these AP2’s should be validated with 
reciprocal co-immunoprecipitation using lysates from tachyzoites and from 
bradyzoites to examine stage-specificity of interactions. Finally, the function of 
these AP2s should be further studied using genetic deletion and transcriptomic 
analysis. 
If AP2IX-4 is a transcriptional repressor of these genes, it can also operate 
by recruiting repressor complexes. Our yeast two-hybrid results identified a 
SWI2/SNF2 Brahma-like putative (TGME49_320300) and SET domain-
containing histone lysine methyltransferase (TGME49_294610), whose 
reciprocal interactions with AP2IX-4 should be validated with co-
immunoprecipitation. The SWI2/SNF2 Brahma-like protein merits further analysis 
as it may serve as a potential chromatin remodeler. SET domain-containing 
histone lysine methyltransferases may activate or repress gene expression 
depending on the particular lysine residue modified. Toxodb.org reveals that this 
protein is downregulated during in vitro bradyzoite conditions; in addition, its cell 
cycle transcript profile demonstrates peak expression in the S/M phase 
(Toxodb.org, 109). The function of this SET domain containing lysine 
methyltransferase is unknown and should be examined to assess its role in 
possible gene expression repression.  
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 To date, no FDA-approved drugs which eradicate T. gondii tissues cysts 
exist. Effective targeting of the chronic of T. gondii infection requires knowledge 
about the molecular processes underlying differentiation and reactivation. 
Emerging literature reveals that differentiation is a complex, multi-step process. 
Understanding the function and mechanism of AP2IX-4, a nuclear, cell-cycle 
regulated factor, will inform how differentiation is coordinated with parasite 
division. Moreover, the dysregulation in bradyzoite gene expression observed in 
Δap2IX-4 parasites suggest a balancing act of gene expression must be 
maintained for efficient cyst formation.  
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APPENDIX 
 
Yeast two-hybrid hits with global predicted biological score (PBS) 
Note: The PBS score calculation and relevance is explained in Chapter 2, 
Section V.I. “N/A” denotes PBS scores which could not be calculated due to 
missing sequences or sequences that are out-of-frame, within 5’ or 3’ UTR 
regions, or antisense compared to their reference CDS.  
 
Gene Annotation PBS 
TGME49_246340 DnaJ domain-containing protein A 
TGME49_215150 AP2X-9 A 
TGME49_257680 myosin light chain MLC1 A 
TGME49_280600 histidyl-tRNA synthetase  B 
TGME49_218960 AP2XII-1 B 
TGME49_282210 AP2VIIa-8 B 
TGME49_311400 WD domain, G-beta repeat-containing protein C 
TGME49_213067 hypothetical protein C 
TGME49_311470 rhoptry neck protein RON5 C 
TGME49_247195 microneme protein MIC15 C 
TGME49_239910 cyclin-dependent kinase C 
TGME49_263060 Proteasome/cyclosome repeat-containing protein D 
TGME49_223840 ATP-citrate lyase D 
TGME49_308880 ImpB/MucB/SamB family protein D 
TGME49_288240 hypothetical protein D 
TGME49_224970 nucleolar protein D 
TGME49_215570 AP2X-11 D 
TGME49_234990 hypothetical protein D 
TGME49_212190 RNA recognition motif-containing protein D 
TGME49_320300 SWI2/SNF2 Brahma-like putative D 
TGME49_270595 UBA/TS-N domain-containing protein D 
TGME49_288700 RecF/RecN/SMC N terminal domain-containing protein D 
TGME49_304990 guanylate-binding protein D 
TGME49_280600 histidyl-tRNA synthetase D 
TGME49_314410 aquarius D 
TGME49_225110 AP2X-2 D 
TGME49_212300 hypothetical protein D 
TGME49_294610 histone lysine methyltransferase, SET  D 
TGME49_287480 hypothetical protein D 
TGME49_215570 AP2X-11 D 
TGME49_304630 ATG C terminal domain-containing protein  D 
TGME49_213020 hypothetical protein D 
TGME49_306320 Myb family DNA-binding domain-containing protein D 
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TGME49_261660  hypothetical protein D 
TGME49_270930  hypothetical protein D 
TGME49_222350  hypothetical protein D 
TGME49_230000  hypothetical protein D 
TGME49_250700  hypothetical protein D 
TGME49_275430  hypothetical protein D 
TGME49_272155  hypothetical protein D 
TGME49_245990  hypothetical protein D 
TGME49_264830  hypothetical protein D 
TGME49_231200  hypothetical protein D 
TGME49_286270  hypothetical protein D 
TGME49_224870  hypothetical protein D 
TGME49_294060  hypothetical protein D 
TGME49_261960  hypothetical protein D 
TGME49_290678  hypothetical protein D 
TGME49_312630 anonymous antigen-1 D 
TGME49_312190 hypothetical protein D 
TGME49_212880 surface antigen repeat-containing protein D 
TGME49_254710 serine esterase (DUF676) protein D 
TGME49_227450 hydrolase, NUDIX family protein D 
TGME49_221640 hypothetical protein D 
TGME49_244450 protein phosphatase 2C domain-containing protein D 
TGME49_264880 NEDD8-activating enzyme E1 catalytic subunit D 
TGME49_257680 myosin light chain MLC1? D 
TGME49_294690 rhomboid protease ROM5? D 
TGME49_249180 DHFR N/A 
TGME49_211650 hypothetical protein N/A 
TGME49_312300 Sec7 domain-containing protein N/A 
TGME49_286420 elongation factor 1-alpha N/A 
TGME49_210800 activator of hsp90 ATPase N/A 
TGME49_243460 hypothetical protein N/A 
TGME49_232350 lactate dehydrogenase LDH1 N/A 
TGME49_257680 myosin light chain MLC1 N/A 
TGME49_318230 phosphoglycerate kinase PGKI N/A 
TGME49_228170 inner membrane complex protein IMC2A N/A 
TGME49_285240 3-oxo-5-alpha-steroid 4-dehydrogenase N/A 
TGME49_205650 AP2VIIa-3 N/A 
None Homolog of SPRED1 (Homo sapiens) D 
None Homolog of p87/89 (Homo sapiens) D 
None Homolog of prosaposin (Homo sapiens) D 
None  Homolog of COL1A1 (Homo sapiens) N/A 
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